Combination therapy

A combination of a selective Raf inhibitor and a MEK inhibitor, like trametinib, addresses the lack of effective treatments for KRAS- and NRAS-mutated tumors by synergistically inhibiting the MAPK pathway, enhancing antitumor responses and reducing side effects in KRAS-mutant NSCLC and NRAS-mutant melanoma.

JP2024160223AInactive Publication Date: 2024-11-13NOVARTIS AG
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024110041
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-04-12
Filing Date
2024-07-09
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for KRAS- and NRAS-mutated tumors, such as KRAS-mutant NSCLC and NRAS-mutant melanoma, lack effective targeted therapies, and existing combinations of MAPK inhibitors often result in toxicity and resistance, necessitating the development of safer and more effective therapeutic options.

Method used

A combination therapy involving a selective Raf inhibitor, such as a compound of formula (I), and a MEK inhibitor like trametinib, which synergistically inhibits the MAPK pathway, effectively targeting KRAS- and NRAS-mutant cancers by blocking heterogeneous and RAS mutation-induced tumorigenesis.

Benefits of technology

The combination of a Raf inhibitor and a MEK inhibitor demonstrates increased antitumor responses in KRAS-mutant NSCLC, NRAS-mutant melanoma, and other cancers, offering a safer and more effective treatment option with reduced side effects compared to monotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160223000035
    Figure 2024160223000035
  • Figure 2024160223000036
    Figure 2024160223000036
  • Figure 2024160223000037
    Figure 2024160223000037
Patent Text Reader

Abstract

To provide a targeted therapy that is safe, is well tolerated, and / or is accompanied with fewer adverse side effects such as skin rash, the targeted therapy being available for patients with KRAS-mutant cancers, such as KRAS mutant NSCLC, and NRAS-mutant cancers, such as NRAS mutant melanoma.SOLUTION: The present invention provides a pharmaceutical combination comprising a Raf inhibitor, which is a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, and a MEK inhibitor, particularly trametinib.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to (a) a compound of formula (I) as defined herein or a pharma- ceutical product thereof. A compound of formula (II) or a pharma- ceutically acceptable salt thereof as defined herein. and (b) a MEK inhibitor, particularly a TRAIL inhibitor, selected from the group consisting of a Raf inhibitor and its acceptable salts. Pharmaceutical combinations containing metinib or a pharma- ceutical acceptable salt or solvate thereof The present invention relates to (a) a compound of formula (I) as defined herein or a pharmaceutical composition thereof A compound of formula (II) or a pharmacopoeitic compound thereof as defined herein, and trametinib or a pharmaceutical composition thereof. The present invention also relates to pharmaceutical combinations comprising a compound selected from the group consisting of a phytochemically acceptable salt or solvate thereof.

[0002] The present invention relates to such combinations for use in the treatment of proliferative diseases, particularly cancer, The use of such combinations for the preparation of a medicament for the treatment of diseases, in particular cancer, proliferative disorders , in particular cancer, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of for the treatment of a proliferative disease, particularly cancer, comprising administering to said subject said combination of Use of such combinations for the treatment of cancer, pharmaceutical compositions containing such combinations and methods for treating cancer It also relates to commercial packaging.

[0003] The present invention relates to a MEK inhibitor, in particular trametinib or a pharma- ceutically acceptable salt or solution thereof. A compound of formula (I) as defined herein for use in combination therapy with a medicament. or a pharma- ceutically acceptable salt thereof, or a compound of formula (II) as defined herein. The present invention also relates to a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof. or a pharma- ceutically acceptable salt thereof, represents a compound of formula (II) as defined herein or a pharma- ceutically acceptable salt thereof; and MEK inhibitors, in particular trametinib or a pharmaceutical equivalent thereof, for use in combination therapy with Acceptable salts or solvates are also provided herein. [Background technology]

[0004] The RAS / RAF / MEK / ERK or MAPK pathway induces cell proliferation, differentiation, and survival. This is a key signaling cascade that leads to tumorigenesis. Dysregulation of this pathway is often This pathway is initiated by the small G protein RAS, which exchanges GDP for GTP. Activated RAS is activated by extracellular signals that subsequently induce Guanidine triphosphatase (GTPase) is a type of enzyme that regulates the function of the RAF (herein referred to as "Raf"). ARAF, BRAF, and Activated RAF proteins promote the activation of MEK1 / 2 proteins. This leads to the phosphorylation and activation of proteins, which in turn activates extracellular signal-regulated kinase (ECK). ERK1 / 2 proteins phosphorylate and activate multiple transcription factors. They phosphorylate a variety of substrates and mediate important cellular activities, including proliferation, differentiation, migration, survival, and angiogenesis. Adjust.

[0005] Aberrant signaling or inappropriate activation of the MAPK pathway is implicated in melanoma, lung and pancreatic cancer. It has been shown to be effective in multiple tumor types, including human cancer, and is involved in the regulation of RAS and BRAF (v-Raf in mouse liver). This occurs through several different mechanisms, including activating mutations in the tumour virus oncogene homologue B1. RAS, a superfamily of GTPases, has many gain-of-function mutations. These proteins can be turned on (activated) by a variety of single point mutations known as KRAS (v-Ki-ras2), a signaling protein regulated by Rat sarcoma viral oncogene homologue (RAS) mutations, especially gain-of-function (GOF ) mutations have been detected in 9-30% of all cancers, and KRAS mutations have a high prevalence The most common is NRAS (86%), followed by NRAS (11%), and HRAS (3%), which is rare. (Cox AD,et al,Nat Rev Drug Discov 2014;1 3(11):828-51). Activating KRAS mutations are associated with melanoma (Fedorenko IV,et al,Br J Cancer 2015;112(2):217-26 ), pancreatic cancer (di Magliano MP&Logsdon CD, Gastroent erology 2013;144(6):1220-9), colorectal cancer (Knickelb ein K&Zhang L, Genes Dis 2015;2(1):4-12) and and ovarian cancer (Nakayama N, et al, Br J Cancer 2008;9 9(12):2020-8) is also seen in many cases.

[0006] Targeted inhibition of downstream effectors of RAS, including RAF, MEK, and ERK kinases The agents have not shown significant clinical activity in RAS-driven tumors. V 600 RAF inhibitors such as vemurafenib, which are effective in mutant melanoma, have been shown to be effective in treating RA Therefore, currently, the treatment of KRAS-mutated and NRAS-mutated tumors is ineffective. There is currently no effective treatment for melanoma with NRAS mutations, unlike BRAF mutations. There are no approved targeted therapies for patients with melanoma. Recent data from the study showed a modest increase in progression-free survival, but (Dummer et al., Lancet Oncology, 2014) col,18,435-445,2017).

[0007] Some vertical combinations of MAPK inhibitors have proven beneficial, but Whether any one of the various permutations of a given combination will be of clinical benefit is not necessarily predictable. For example, in combination with the ERK1 / 2 inhibitor GDC-0994, It has recently been reported that the combination of the MEK inhibitor cobimetinib results in overlapping and cumulative toxicity. This, according to the authors, limits the further development of this particular combination. (Weekes et al 2017, Abstract CT107:A ACR Annual Meeting 2017;April 1-5, 2017 Combinations)

[0008] Lung cancer is a common type of cancer that affects men and women worldwide. NSCLC is the most common type of lung cancer. It is the most common form (approximately 85%), and approximately 70% of these patients have advanced disease at the time of diagnosis. Approximately 30% of NSCLC tumors present with stage IIIB or stage IV disease. These mutations are mediated by the epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI resistance is associated with d 2005;2(1):e17). Approved for use in patients with NSCLC with BRAF mutations other than 600E There is no targeted therapy available.

[0009] Melanoma is a common type of cancer that affects men and women worldwide. Fifty percent of patients harbor activating BRAF mutations and 20% of these patients harbor activating NRAS mutations. (Zhang et al., Pigment Cell Melanom a Res 2016;29:266-283. NRAS mutations are associated with stage IV melanoma was identified as an independent predictor of shorter survival after diagnosis of rheumatoid arthritis (Jakob JA et al. (2012),Cancer,Volume 118, Issue 16,Pages 4014-4023). Summary of the Invention [Problem to be solved by the invention]

[0010] Thus, direct inhibition of KRAS and NRAS has proven to be challenging. To date, we have been investigating the efficacy and safety of KRAS-mutated NSCLC and other cancers with NRAS mutations. No approved targeted therapies are available for patients with NRAS-mutated cancers, such as laminoma. Thus, it is safe, well tolerated, and / or associated with no adverse effects, such as rash. There is a need for targeted therapies with fewer side effects. There is also a need for treatments that provide a positive response. [Means for solving the problem]

[0011] MEK inhibitors and combinations thereof as defined herein that potently inhibit the activity of both CRAF and BRAF. Combination with a selective Raf inhibitor, such as a compound of formula (I) as described above, inhibits BRAF mutations. These results suggest that this compound may be effective in preventing tumor formation induced by heterologous tumors and RAS mutations. It has been found that the combination of the compound of formula (I) with trametinib inhibits NRAS mutations. and was found to be synergistic in MAPK-mutated cancer cell lines, including KRAS-mutated cell lines. Based on the findings described herein, Raf inhibitors, particularly CRAs such as compounds of formula (I) Combining BRAF and BRAF inhibitors with MEK inhibitors such as trametinib has been shown to inhibit RAS modulation. It may be particularly effective and less likely to cause resistance in patients with heterologous tumors.

[0012] The combination of the compound of formula (I) with trametinib is useful in the treatment of human KRAS mutant NSCLC, In RC and PDAC xenograft models and human NRAS mutant melanoma xenograft models The compound of formula (II) and Combination with trametinib demonstrated potent anti-cancer drugs in a human HPAFII pancreatic xenograft mouse model. The compound of formula (I) showed increased efficacy in tumor response compared to either monotherapy. The compound or compound of formula (II) inhibits the MAPK pathway, both alone and in combination with a MEK inhibitor. These cancers may be useful in treating patients with cancers that harbor these alterations. , KRAS mutant NSCLC (non-small cell lung cancer), KRAS mutant pancreatic cancer (e.g., KRAS mutant pancreatic ductal adenocarcinoma (PDAC), KRAS-mutated CRC (colorectal cancer), and NRAS-mutated melanoma Included.

[0013] Accordingly, the present invention provides: (a)(i) a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof, and (ii) a compound of formula (II) or a pharma- ceutically acceptable salt thereof; and (b) MEK inhibitors, in particular trametinib or a pharma- ceutically acceptable salt or solvate thereof. The present invention provides a pharmaceutical combination comprising: Such combinations are also offered.

[0014] Furthermore, the present invention relates to a method for producing a (a) MEK inhibitors, in particular trametinib or a pharma- ceutically acceptable salt or solvate thereof. (i) a compound of formula (I) as defined herein for use in combination therapy with or a pharma- ceutically acceptable salt thereof, and (ii) a compound of the formula II) or a pharma- ceutically acceptable salt thereof; Agents, and (b)(i) a compound of formula (I) as defined herein or a pharma- ceutically acceptable derivative thereof; and (ii) a compound of formula (II) or a pharmaceutical composition thereof as defined herein. and a Raf inhibitor selected from the group consisting of a therapeutically acceptable salt thereof MEK inhibitors, particularly trametinib or a pharma- ceutically acceptable salt or solvate thereof, for thing to provide.

[0015] The compound of formula (I) has the following structure: [ka] It is a compound having the formula:

[0016] The compound of formula (II) has the following structure: [ka] It is a compound having the formula:

[0017] The present invention relates to the use of the compounds described herein for simultaneous, separate or sequential use, in particular in the treatment of proliferative disorders. or a pharma- ceutically acceptable salt thereof, and a MEK inhibitor and preferably trametinib or a pharma- ceutical acceptable salt or solvent thereof. Further combinations are provided.

[0018] In another preferred embodiment, the pharmaceutical combination of the present invention comprises (a) a Raf inhibitor, of the formula ( I) a compound of formula I or a pharma- ceutically acceptable salt thereof, and (b) trametinib or a pharma- ceutically acceptable salt thereof. The term also includes acceptable salts or solvates thereof, particularly solvates thereof.

[0019] In another preferred embodiment, the pharmaceutical combination of the present invention comprises (a) a Raf inhibitor, of the formula ( II) or a pharma- ceutically acceptable salt thereof, and (b) trametinib or a pharma- ceutically acceptable salt thereof. This includes acceptable salts or solvates, particularly solvates thereof.

[0020] The present invention relates in particular to a method for treating RA, which is characterized by activating mutations in the MAPK pathway. One or more mutations in S (e.g., KRAS or NRAS) and / or BRAF The present invention also relates to a combination of the present invention for use in the treatment of a cancer characterised by a

[0021] The present invention also provides the use of the combination of the present invention for the treatment of a proliferative disease, in particular cancer. In particular, the combination of the present invention is useful in the treatment of non-small cell lung cancer (NSCLC), melanoma, pancreatic ductal adenocarcinoma (P These may be useful in the treatment of cancer such as pulmonary arterial (DAC), cervical cancer, ovarian cancer or colorectal cancer (CRC).

[0022] The present invention relates to a combination according to the invention for the preparation of a medicament for the treatment of a proliferative disease, in particular cancer. The use of the

[0023] The present invention relates to a method of treating a proliferative disease, comprising administering to said patient a therapeutically effective amount of The combination of the present invention may be administered simultaneously, separately or in combination to a subject in need thereof in an amount effective to treat the disease. The method also includes administering

[0024] The present invention relates to a method for treating a proliferative disease comprising administering to a patient a combination of the present invention in an amount that is jointly therapeutically effective against the proliferative disease. and optionally at least one pharma- ceutical composition or combination comprising the compound of formula (I) and optionally at least one pharma- ceutical acceptable carrier. Combined preparations are also provided.

[0025] The present invention relates to (a)(i) a compound of formula (I) or and (ii) a compound of formula (II) or a pharma- ceutically acceptable salt thereof. (b) one or more dosage units of a Raf inhibitor selected from the group consisting of a salt thereof; an inhibitor, preferably trametinib or one of its pharma- ceutically acceptable salts or solvates; also provides combination preparations comprising multiple dosage units.

[0026] The present invention relates to a method for treating proliferative diseases, preferably non-small cell lung cancer (NSCLC), melanoma, pancreatic ductal adenocarcinoma, and the like. for use in the treatment of prostate cancer (PDAC), cervical cancer, ovarian cancer or colorectal cancer (CRC); for simultaneous, separate or sequential administration of the combination of the present invention to a patient in need thereof, the active ingredients Also provided is a commercial package containing the combination of the invention as a pharmaceutical composition and instructions.

[0027] The present invention relates to the use of MEK inhibitors, preferably trametinib or its analogs, in the treatment of proliferative diseases. (i) for simultaneous, separate or sequential use with a pharma- ceutically acceptable salt or solvate of (I) a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and (ii) a compound of formula (ii) or A commercially available product comprising a Raf inhibitor selected from the group consisting of pharma- ceutically acceptable salts thereof and instructions. The Company also provides packaging for use.

[0028] Various aspects of the invention are described in further detail below. Additional definitions are provided throughout the specification. and explain. [Brief description of the drawings]

[0029] [Figure 1] Compound of formula (I) in Fig. 1) Calu-6 (KRAS(Q61K) mutant), Fig. 2) NCI-H358 (KRAS(G12C) mutant), Fig. 3) HLUX1156 (KRAS(G12C) mutant), and Fig. 4) NCI-H727 (KRAS(G12V) mutant) xenograft lung cancer tumor models in mice. Animals bearing subcutaneous xenografts were treated with compound of formula (I) as indicated. Compounds were administered orally (PO) daily (qd or QD), twice daily (bid or BID) or every other day (q2d or Q2D) as indicated. Antitumor activity was determined by assessing the percentage of tumor volume in the treatment group relative to the tumor volume in the vehicle-treated group (% T / C) or the percentage of tumor regression (i.e., the volume of the tumor after treatment compared to the starting volume (regression (%) (indicated as "% Reg" or "~% Reg" in Figures 1-4). SEM = standard error of the mean, PBS = phosphate-buffered saline). [Diagram 2] (As stated above.) [Diagram 3] (As stated above.) [Figure 4] (As stated above.) [Diagram 5]FIG. 2 depicts the efficacy of the compound of formula (I) and the MEK inhibitor trametinib used in combination in the Calu-6 xenograft tumor model in mice. Animals bearing subcutaneous xenografts of Calu-6 were treated with the compound of formula (I) and / or trametinib as indicated. Both the depth (FIG. 5) and durability of response (FIG. 6) were shown. Compounds were administered orally every day (qd) or every other day (q2d) as indicated. Antitumor activity was determined by assessing the percentage of tumor volume in the treatment group relative to the tumor volume in the vehicle-treated group (% T / C) or the percentage of tumor regression compared to the starting volume (% Regression, indicated as "% Reg" in FIGS. 2A-2B). [Figure 6] (As stated above.) [Figure 7] Cell lines harboring different BRAF or RAS mutations were treated with the indicated concentrations of DMSO, dabrafenib or the compound of formula (II) for 2 hours. Inhibition of MEK or ERK phosphorylation was measured by Western blot analysis. The compound of formula (II) inhibits oncogenic signaling and proliferation in tumor cells harboring BRAF, NRAS or KRAS mutations with minimal paradoxical activation. [Figure 8] Growth inhibition of cell lines was determined after 5 days of treatment with dabrafenib (top panel) or a compound of formula (II) (bottom panel). [Figure 9] Dot plot of IC50 values ​​of growth inhibition in 357 human cancer cell lines by the compound of formula (II) or dabrafenib after 3 days of inhibitor treatment. The dotted line represents an IC50 of 5 μM, which was used as a cutoff for cell line sensitivity to the inhibitor. The number of cell lines sensitive and resistant to each inhibitor in BRAF mutant, KRAS mutant, NRAS mutant or wild type (WT) cells is shown below the graph. Fisher's exact test was performed to determine the statistical significance of inhibitor activity in BRAF or RAS mutant cell lines versus WT cell lines. [Figure 10]Tumor samples were collected at the indicated time points following a single dose of vehicle or increasing doses of a compound of formula (II) in Calu-6 tumor-bearing animals, and phosphorylated MEK (pMEK) levels were determined. pMEK levels are expressed as the ratio of pMEK / total MEK in the treatment groups compared to vehicle controls at each time point. [Figure 11] Growth inhibition of Calu-6 tumor xenografts was measured after treatment with vehicle or compound of formula (II) across four dose levels. Tumor volumes are expressed as the mean tumor volume ± standard error of the mean (SEM) of six animals per treatment group. Animals bearing subcutaneous xenografts of Calu-6 were treated with compound of formula (II) as indicated. Compound of formula (II) was administered daily (qd). Antitumor activity was determined by assessing the ratio of tumor volume in the treatment group to the tumor volume in the vehicle-treated group (% T / C) or the percentage of tumor regression compared to the starting volume (% Regression, shown as "% Reg" in Figure 11). [Figure 12] The in vivo antitumor activity of the compound of formula (II) was evaluated in a panel of 23 NSCLC patient-derived xenograft (PDX) models and presented as the % change in tumor volume at the time of measurement compared to the initial tumor volume. Positive values ​​indicate tumor growth and negative values ​​indicate tumor regression. The compound of formula (II) was administered orally once daily at 60 mg / kg or 200 mg / kg (indicated by ▼). Each tumor was annotated with BRAF or RAS mutation status. For comparison, tumor response to paclitaxel in a panel of NSCLC PDX models was included. GOF=gain of function, WT=wild type. [Figure 13]The antiproliferative combination activity of the compound of formula (II) with trametinib in cells derived from HPAF-II (KRAS(G12D mutated) pancreas) was evaluated. Top left panel: Dose matrix representing the percentage of growth inhibition relative to DMSO by the compound of formula (II), trametinib and the combination after 5 days of treatment. Top right panel: Excess inhibition values ​​representing the deviation between the combination effect and the calculated additive effect of the two single agents using the Loewe model. The calculated Loewe synergy scores are shown. Bottom panel: Isobologram analysis of the dose matrix data, the dark grey lines represent the data points and the light grey lines indicate additivity. The calculated Loewe combination index (CI) at 50% growth inhibition is shown. [Figure 14] In vivo activity of the compound of formula (II) and trametinib as single agents or in combination in HPAF-II xenograft model. Signal transduction inhibition after single dose treatment measured by DUSP6 (dual specificity phosphatase 6) mRNA levels. Furthermore, effective dosage can be determined by monitoring biomarkers that indicate MAP kinase pathway inhibition. Specifically, DUSP6 is a known biomarker of this pathway, and in vivo levels of DUSP6 have been shown to be reduced in response to the compound of formula (II) with effective plasma concentrations. DUSP6 levels are expressed as percentage change compared to vehicle group after normalization to the control gene RPLPO. [Figure 15] In vivo activity of the compound of formula (II) and trametinib as single agents or in combination in the HPAF-II xenograft model. In vivo tumor growth after 10 days of treatment as indicated. Compounds were administered daily (qd). Antitumor activity was determined by assessing the percentage of tumor volume in the treated group relative to the tumor volume in the vehicle-treated group (% T / C) or the percentage of tumor regression compared to the starting volume (% Regression, shown as "% Reg" in Figure 15). [Figure 16]In vivo activity of the compound of formula (I) (Compound I in the figure) and trametinib as single agents or in combination in the HCT116 xenograft model. In vivo tumor growth after 17 days of treatment as indicated. Compounds were administered daily (qd) or every other day (q2d). Antitumor activity was determined by assessing the percentage of tumor volume in the treated group relative to the tumor volume in the vehicle-treated group (% T / C) or the percentage of tumor regression compared to the starting volume (% Regression, shown as "% Reg" in Figure 16). [Figure 17] In vivo activity of the compound of formula (I) (Compound I in the figure) and trametinib as single agents or in combination in the 2043 xenograft model. In vivo tumor growth after 21 days of treatment as indicated. Compounds were administered daily (qd) or every other day (q2d). Antitumor activity was determined by assessing the percentage of tumor volume in the treated group relative to the tumor volume in the vehicle-treated group (% T / C) or the percentage of tumor regression compared to the starting volume (% Regression, shown as "% Reg" in Figure 17). [Figure 18] In vivo activity of the compound of formula (I) (Compound I in the figure) and trametinib as single agents or in combination in the SKMEL30 xenograft model. In vivo tumor growth after 22 days of treatment as indicated. Compounds were administered daily (qd) or twice daily (bid). Antitumor activity was determined by assessing the percentage of tumor volume in the treated group relative to the tumor volume in the vehicle-treated group (% T / C) or the percentage of tumor regression compared to the starting volume (% Regression, shown as "% Reg" in Figure 18). [Figure 19]In vivo activity of the compound of formula (I) (Compound I in the figure) and trametinib as single agents or in combination in the 20667 xenograft model. In vivo tumor growth after 17 days of treatment (single agents) and 31 days of combination treatment as indicated. Compounds were administered daily (qd) or twice daily (bid). Antitumor activity was determined by assessing the percentage of tumor regression compared to the starting volume (% regression, shown as "% Reg" in Figure 19) at day 34 for single agents or day 48 for combinations. [Figure 20] In vivo activity of the compound of formula (I) (Compound I in the figure) and trametinib as single agents or in combination in the 21124 xenograft model. In vivo tumor growth after 21 days of treatment as indicated. Compounds were administered daily (qd) or twice daily (bid). Antitumor activity was determined by assessing the percentage of tumor volume in the treated group relative to the tumor volume in the vehicle-treated group (% T / C) or the percentage of tumor regression compared to the starting volume (% Regression, shown as "% Reg" in Figure 20). [Figure 21] In vivo activity of the compound of formula (I) (Compound I in the figure) and trametinib as single agents or in combination in the 20864 xenograft model. In vivo tumor growth after 14 days of treatment (single agents) and 36 days of combination treatment as indicated. Compounds were administered daily (qd) or twice daily (bid). Antitumor activity was determined by assessing the percentage of tumor regression compared to the starting volume (% regression, shown as "% Reg" in Figure 21) at day 33 for single agents or day 55 for combinations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] The present invention relates to a compound of formula (I) as defined herein or a pharmaceutical composition thereof. and (ii) a compound of formula (II) as defined herein or a compound thereof, or a pharma- ceutical acceptable salt thereof; and (b) a Raf inhibitor selected from the group consisting of and a MEK inhibitor for use in the treatment of a proliferative disorder.

[0031] As used herein, the term "Raf inhibitor" refers to a serine / threonine-protein Selectively targeting or reducing the activity of at least one of the kinases B-Raf or C-Raf. B-Raf protein kinase (herein b-RAF, B RAF or b-Raf and C-Raf protein kinases (referred to herein as c-RAF, also known as CRAF or c-Raf, competes for adenosine triphosphate (ATP). Raf inhibitors preferentially inhibit both Raf monomers and Raf dimers. To harm.

[0032] As used herein, a Raf inhibitor is a compound represented by the formula (I) as defined herein. or a pharma- ceutically acceptable salt thereof, and (ii) as defined herein or a pharma- ceutically acceptable salt thereof.

[0033] The compound of formula (I) has the following structure: [ka] has.

[0034] For convenience, this group of compounds and salts thereof will be referred to collectively as "compounds of formula (I)" or "compounds (I)" which is an alternate reference to "a compound of formula (I)" or "compound (I)." The term "compound" as used herein is intended to refer to either the compound or a pharma- ceutically acceptable salt thereof.

[0035] The Raf inhibitors, compounds of formula (I) and pharma- ceutically acceptable salts thereof, are incorporated herein by reference in their entirety. The method is described in International Publication No. WO 2014 / 151616, which is incorporated herein by reference. and a method for its preparation is described, for example, in Example 1156 therein.

[0036] The compound of formula (II) has the following structure: [ka] has.

[0037] For convenience, this group of compounds and salts thereof will be referred to collectively as "compounds of formula (II)" or "compounds "Compound (II)" which is a reference to "a compound of formula (II)" or "compound (II)". and interchangeably refer to either the compound or a pharma- ceutically acceptable salt thereof. do.

[0038] The Raf inhibitors, compounds of formula (II) and pharma- ceutically acceptable salts thereof, are herein incorporated by reference in their entirety. No. 5,999,333, which is incorporated herein by reference. and a method for its preparation is described, for example, in Example 131 therein.

[0039] In a cell-based assay, a Raf inhibitor, a compound of formula (I) and a compound of formula (II) Antiproliferative activity in cell lines containing various mutations that activate MAPK signaling In vivo, treatment with a compound of formula (I) or a compound of formula (II) resulted in the induction of N SCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS It led to tumor regression in several KRAS mutant models, including G12C. When this is done, it is observed that the compound of formula (I) or the compound of formula (II) at a dose that is well tolerated. The observed in vitro and in vivo MAPK pathway inhibitory and antiproliferative activity of the compound of formula (I) or a compound of formula (II) is administered to a patient having a tumor with an underlying activation defect in the MAPK pathway. It is further suggested that the compound of formula (I) may have antitumor activity in patients with and the compound of formula (II) maintains the kinase pocket in an inactive conformation, thereby Reduces the paradoxical activation seen with many B-Raf inhibitors and suppresses mutant Ras-induced signaling ATP-competitive interactions of both B-Raf and C-Raf type 2, which inhibits signal transduction and cell proliferation The compounds of formula (I) and (II) are inhibitors of a number of MAPK-induced hi in human cancer cell lines and in human lesions in the KRAS, NRAS and BRAF oncogenes. Efficacy was demonstrated in xenograft tumors representative of endogenous model tumors.

[0040] The pharmaceutical combination of the present invention further comprises a MEK inhibitor. The term "MEK inhibitor" refers to As used herein, the term "antibody" refers to an antibody that inhibits the activity of at least one of MAP / ERK kinase 1 and 2 (MEK1 / 2). The term "antibody" is defined to refer to compounds that target, decrease or inhibit the activity of certain receptors.

[0041] MEK inhibitors suitable for use in the combination of the present invention include, but are not limited to, a) Trametinib (N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodo) (dophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- Tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetate mide) (also called JPT-74057 or GSK1120212) or its pharmaceutical Trametinib is incorporated herein by reference in its entirety, or a commercially available, commercially available salt or solvate thereof. Disclosed in Example 4-1 of the incorporated International Publication No. WO 2005 / 121142. As monotherapy, trametinib inhibits B-Raf V600E or V600K It is approved for the treatment of unresectable or metastatic melanoma with the mutation and The compound is commercially available from Novartis AG under the trade name Mekinist®. It is available as: b) PD0325901 (Pfizer) (International Publication No. 02 / 06213) PD184352 (Pfizer); refametinib (RDEA1 19 or Bay 86-9766); cobimetinib (also known as XL518) It is commercially available from Roche under the trade name Cotellic®. );AS-701255(Merck Serono);AS-701173(Merck ck Serono; Pimasertib (AS-703026 or MSC1936369B) (Merck Serono); RDEA 436 (Ardea Biosciences); RO4987655 (RG7167 and (also called) (Roche) and / or RG7420 (also called GDC-0623) (Roche) or a pharma- ceutically acceptable salt thereof Includes:

[0042] Preferably, the MEK inhibitor is trametinib or a pharma- ceutically acceptable salt or solution thereof. In some preferred embodiments, trametinib is a dimethylsulfoxy In some embodiments, trametinib is in the form of a sodium salt solvate. Suitably, trametinib is in the form of a hydrate, acetate, ethanol, nitromethane, chloroform, Benzene, 1-pentancol, isopropyl alcohol, In the form of a solvate selected from ethylene glycol and 3-methyl-1-butanol These solvates and salt forms are described in WO 2005 / 121142. These can be prepared by one skilled in the art from the descriptions therein.

[0043] The present invention relates to a method for the simultaneous, separate or sequential use of (a) i) a compound of formula (I) as defined herein or a pharma- ceutically acceptable salt thereof; and (ii) a compound of formula (II) as defined herein or a pharma- ceutically acceptable salt thereof. and (b) a MEK inhibitor. Further regarding combinations.

[0044] Selected terms are defined below and throughout this application. Compounds of the Invention The terms used herein are used interchangeably with "nomenclature" unless otherwise defined. All technical and scientific terms used herein are understood by those of ordinary skill in the art to which this invention belongs. Unless otherwise specified, the following terms are used herein to refer to the same The general definitions shall apply.

[0045] As used herein, the term "combination of the present invention" means (a)(i) any of the compounds defined herein; (ii) a compound of formula (I) or a pharma- ceutically acceptable salt thereof, as defined herein; A compound of formula (II) as defined in the specification or a pharma- ceutically acceptable salt thereof. and (b) a MEK inhibitor, in particular trametinib or a pharmaceutical formulation thereof. Raf inhibitors are combinations of compounds that are either phytochemically or chemically acceptable. A compound of formula (I) or a pharma- ceutically acceptable salt thereof and a MEK inhibitor, preferably trametinib. tinib, or a pharma- ceutically acceptable salt or solvate thereof, or a Raf inhibitor, or a pharma- ceutically acceptable salt thereof, and a MEK inhibitor, preferably trametinib or The pharma- ceutically acceptable salt or solvate thereof is a unit pharmaceutical composition containing both compounds. They can be used in combination according to the present invention by simultaneous administration in The combination may be combined with another pharmaceutical composition, each of which includes one of a Raf inhibitor and a MEK inhibitor. In a sequential manner (where, for example, a Raf inhibitor or a MEK inhibitor is first One may be administered first, the other second. Such sequential administration may be performed over time. can be close together (eg, simultaneously) or separate.

[0046] As used herein, the terms "a" and "b" in the context of describing the present invention "An" and "the" and similar references are used herein wherever possible. Unless otherwise indicated or clearly contrary to the context, both the singular and the plural are used. When the plural is used for compounds, salts, etc., This is taken to mean also single compounds, salts, etc.

[0047] The term "or" is used herein to mean either or, unless the context clearly dictates otherwise. Used to mean and / or, and is used interchangeably with the term and / or will be done.

[0048] "About" and "approximately" generally refer to the quantity measured, taking into account the nature or precision of the measurements. An exemplary degree of error is given for a given value or Within 20 percent (%) of the range of values, typically within 10%, and more typically within 5% When a dosage amount is described herein as "about" a specified amount, the actual dosage is may vary by up to 10% from the stated amount, and this use of "about" does not necessarily imply that a given The precise amount within the dosage form may be varied to provide a variety of dosage forms without substantially affecting the in vivo efficacy of the administered compound. It is understood that amounts may vary slightly from those intended for a variety of reasons.

[0049] When dosages are described herein as specified amounts, i.e., without the term "about," In this case, the actual dosage may vary up to 10% (preferably up to 5%) from the amount stated. This usage indicates that the precise amount in a given dosage form determines the in vivo efficacy of the administered compound. The amount may vary slightly from the intended amount for a variety of reasons without materially affecting the results. It is understood that.

[0050] The terms "comprises" and "included" are used herein unless otherwise stated. To the extent that the term is used in its open-ended and non-limiting sense,

[0051] "Combination" or "combined with" means that the therapeutic or therapeutic agents must be physically mixed together. must be administered simultaneously and / or formulated for delivery together. Although this does not imply that these delivery methods must be used in combination with the methods described herein, The therapeutic agents in these combinations may be one or more other additional The therapeutic agent may be administered in combination with, prior to, or subsequent to, the therapeutic or therapeutic agent of interest. The therapeutic agents may be administered in any order. Generally, each agent is administered in a sequential order. The combination will be administered at a prescribed dose and / or time schedule. The additional therapeutic agents utilized in the method may be administered together in a single composition or in different compositions. It will be further understood that the compositions may be administered separately in a single formulation. Additional therapeutic agents used should be administered at levels not exceeding the levels at which they are administered individually. In some embodiments, the levels utilized in combination are comparable to those of monotherapy. This is probably below the level that would be used as law.

[0052] The combinations of the present invention may have therapeutic or protective functions or both. These molecules are useful for treating and / or preventing various disorders, such as cancer, as described herein. The compound can be administered to a human subject for

[0053] As used herein, the terms "combination," "therapeutic combination," or "pharmaceutical combination" refer to "Combination" means a fixed or non-fixed combination in one dosage unit form. A combination or set of components for combined administration, where two or more therapeutic agents are together, simultaneously, independently or within time intervals (especially those time intervals, administered separately (where the partners may have a synergistic, i.e. additive, effect) It's possible.

[0054] The term "combination therapy" refers to a combination of two or more therapeutic agents for treating a therapeutic condition or disorder described in this disclosure. This refers to the administration of one or more therapeutic agents in a substantially simultaneous manner for each active ingredient. formula, e.g. in a single formulation with a fixed ratio of active ingredients or in separate formulations (e.g. This includes the co-administration of these therapeutic agents in a single dose (in a capsule and / or intravenous formulation). The administration of each type of treatment may be at approximately the same time or at different times, in a sequential or separate manner. The use of the active ingredients in a single formulation or in separate formulations is also included. Regardless of whether the drug is administered or not, it is administered to the same patient as part of the same course of treatment. In any case, the treatment regimen will be intended to treat the conditions or disorders described herein. This provides beneficial effects in

[0055] Simultaneous therapeutic use, within the meaning of the present invention, means administration by the same route and at the same time or effect. It refers to the administration of at least two active ingredients at qualitatively the same time.

[0056] Separate uses, within the meaning of the present invention, are in particular those at the same time or substantially at the same time by different routes. It refers to the administration of at least two active ingredients at the same time.

[0057] Sequential therapeutic use refers to the administration of at least two different drugs at different times, using the same or different routes of administration. More specifically, the method of administration refers to the administration of one type of active ingredient in its entirety. By "administration of one or more of the two" is meant a method that is performed before administration of the other begins.

[0058] As used herein, the terms "fixed combination," "fixed dose," and " A "single formulation" provides a patient with both therapeutic agents in amounts that are jointly therapeutically effective for the treatment of cancer. A single vehicle refers to a single carrier or vehicle or dosage form that is formulated to deliver a The pharmaceutical compositions are designed to deliver an amount of each drug together with any pharma- ceutically acceptable carrier or excipient. In some embodiments, the vehicle is designed to be a tablet, capsule, pill, or pack. In another embodiment, the vehicle is a solution or suspension.

[0059] The term "non-fixed combination" or "set of components" refers to the combination of the present invention. Both drugs are separate entities, either simultaneously, in parallel or consecutively without any specific time limit. administered to a patient (wherein such administration results in a therapeutic effect in the body of a subject in need thereof). The latter refers to a cocktail of drugs that provides therapeutically effective levels of two compounds. This also applies, for example, to the administration of three or more active ingredients.

[0060] As used herein, the term "pharmaceutical acceptable" means a drug that has reasonable benefit / risk. Excessive toxicity, irritation, allergic reactions, or other problems or complications commensurate with the within the bounds of sound medical judgment, appropriate for contact with subject, e.g., mammalian or human tissue. "compounds, materials, compositions and / or dosage forms" refers to compounds, materials, compositions and / or dosage forms that are within the

[0061] As used herein, the term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable The "carrier" may include any solvent, dispersion medium, coating, surfactant, etc. that would be known to one of skill in the art. , antioxidants, preservatives (e.g., antibacterial and antifungal agents), isotonicity agents, absorption delaying agents, salts, preservatives , drugs, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavorings, dyes, etc. Any conventional carrier may be used, except insofar as it is incompatible with the active ingredient. The use thereof in a method of treatment or pharmaceutical composition is contemplated.

[0062] The term "pharmaceutical composition" as used herein refers to a pharmaceutical composition for treating a particular disease or condition affecting a subject. at least one therapeutic agent to be administered to a subject, e.g., a mammal or a human, to The pharmaceutical combination of the present invention is defined as a mixture or solution containing: Pharmaceutical compositions suitable for enteral or parenteral administration, such as tablets, capsules, or suppositories, or ampoules Unless otherwise indicated, these can be formulated in any suitable manner known per se. In some cases, the process may involve a variety of conventional techniques, such as blending, grinding, direct compression, etc., which will be readily apparent to those skilled in the art. Prepared by granulation, sugar-coating, dissolving, freeze-drying processes or manufacturing techniques. In each dosage form, individual doses are added so that the required effective amount can be reached by administration of the unit. The unit content of the combination partner contained does not necessarily constitute an effective amount by itself. It will be understood that the pharmaceutical composition contains from about 0.1% to about 99.9%, preferably about 1%. The therapeutic agent may contain up to about 60% of the therapeutic agent. Without undue burden, one or more of the above-mentioned carriers may be used with respect to the particular desired properties of the dosage form. The amount of each carrier used will vary within the ordinary ranges of those skilled in the art. The following references disclose techniques and excipients used to formulate oral dosage forms: The Handbook of Pharmaceutical Excip ients,4th edition,Rowe et al.,Eds.,Ameri can Pharmaceuticals Association (2003); and Remington: the Science and Practice of Ph. armacy,20th edition,Gennaro, Ed.,Lippinc ott Williams & Wilkins (2003). These optional additional Conventional carriers can be incorporated into the initial mixture prior to or during granulation. or by incorporating one or more conventional carriers into the oral dosage form. Incorporating it into an oral dosage form by combining it with granules containing the individual drugs of the combination In the latter embodiment, the combined mixture can be passed through, for example, a V-mixer. The mixture may be further blended and then compressed or molded into tablets, e.g., monolithic tablets, or encapsulated. The composition may be enclosed in a capsule or filled into a sachet.

[0063] Pharmaceutical compositions are formulated in unit dose form containing a predetermined amount of active ingredient per unit dose. In certain embodiments, a unit dose can be provided in a dosage form, where each vehicle is a The pharmaceutical composition according to the present invention is a pharmaceutical composition comprising at least one therapeutic agent in an effective amount together with a pharmaceutical acceptable carrier and excipient. In some embodiments, the unit dose is administered to a patient simultaneously. The present invention relates to one or more tablets, capsules, pills, injections, infusions, patches, etc. As is known to those skilled in the art, the amount of active ingredient per dose will vary depending on the condition being treated, the route of administration and the patient. The preferred unit dosage composition is a daily dose of or sub-dose, or an appropriate fraction thereof, of the active ingredient. The pharmaceutical compositions may be prepared by any of the methods well known in the art of pharmacy. This can be done.

[0064] The pharmaceutical compositions of the invention may contain a "therapeutically effective amount" or an "effective amount" of a compound of the invention. The term "pharmacologically effective amount," "therapeutically effective amount," or "clinically effective amount" of a therapeutic agent The combination provides a therapeutic benefit in reducing the clinically observable signs and symptoms of the disorder being treated with the combination. The dosage and efficacy data required to provide an observable or clinically significant improvement to baseline A therapeutically effective amount is determined based on factors such as the individual's condition, age, sex, and weight. A therapeutically effective amount is an amount that is sufficient to address any toxic or detrimental effects of a therapeutic agent. A "therapeutically effective dose" is also an amount that is greater than the therapeutically beneficial effect of a given drug. It is preferred that the compound modulates a measurable parameter, such as disease progression, in a desired manner. The ability to adjust configurable parameters allows for establishing suitable dosing levels and schedules. To facilitate validation, therapeutic agents should be evaluated in animal model systems that are predictive of efficacy in human tumors. Alternatively, this property of the composition can be determined using in vitro assays known to those of skill in the art. Compounds are evaluated by examining their ability to modulate undesirable parameters. It can be valued.

[0065] As used herein, the term "jointly therapeutically active" or "joint therapeutic effect" refers to a therapeutic The subject to be treated, particularly a human, still needs to have a (preferably synergistic) interaction (co-action). The therapeutic agents may be administered jointly, separately or sequentially at time intervals that provide a therapeutic effect. In particular, whether this is the case can be determined by tracking blood levels of the compound. and determining whether any of the following is present in the blood of the person being treated for at least a certain time interval: Both compounds are shown to be present.

[0066] As used herein, the term "agent" refers to a substance that is capable of acting as a therapeutic agent in a tissue, system, animal, mammal, human or other subject. It is understood that the term "drug" means a substance that produces a desired effect in a subject. It is also understood that the compound may be a combination or composition of two or more compounds. It should be.

[0067] The term "proliferative disease" is preferably cancer.

[0068] As used herein, the term "cancer" refers to the unwanted and uncontrolled growth of abnormal cells. Cancer cells spread locally or through the bloodstream and lymphatic system to other parts of the body. As used herein, the term "cancer" or "tumor" includes any cancer that can spread to any part of the body. The term "cancer" as used herein includes all solid and malignant cancers and tumors. The term is used to refer to a broad range of tumors, including hematologic and hematological malignancies.

[0069] "Oral dosage form" means a unit dosage form formulated or intended for oral administration. Included.

[0070] As used herein, the terms "treat," "treatment," and "treating" refer to a disorder. For example, reducing or ameliorating the progression, severity and / or duration of a proliferative disorder or one or more therapeutic options. one or more symptoms of the disorder resulting from the administration of the treatment, suitably one or more discernible symptoms In specific embodiments, the terms "treat," "treatment," and "treating" refer to an improvement in is characterized by at least one proliferative disorder, such as tumor growth, that is not necessarily discernible by the patient. In another embodiment, the term "treat" refers to the improvement of one or more measurable physical parameters. "Treatment" and "treating" include any physical or mental improvement, for example, by stabilization of discernible symptoms. The present invention provides a method for the prevention of proliferation disorders, for example by stabilizing physiological parameters, or both. In another embodiment, the terms "treat", "treatment" and "treating" are used interchangeably. " refers to a reduction or stabilization of tumor size or cancer cell number.

[0071] Within the meaning of this disclosure, the term "treat" refers to preventing a disease, as well as initiating (i.e., preventing or reducing) the onset of the disease. delay the onset of clinical symptoms and / or reduce the risk of developing or worsening the disease The term "protect" as used herein refers to reducing the immune system of a subject, e.g., a mammal or human. Prevent, delay or treat the onset, persistence or progression of disease in or It is used to mean all of these as appropriate.

[0072] The term "subject" or "patient" as used herein includes any person who is suffering from cancer or any disorder (directly This includes animals that may be suffering from or afflicted by diseases that are directly or indirectly involved in cancer. Examples of subjects include mammals, e.g., humans, apes, monkeys, dogs, etc. , cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats and transgenics In a preferred embodiment, the subject is a human, e.g., a patient suffering from an increase in, for example, cancer. A human suffering from, at risk of suffering from, or potentially suffering from a reproductive disorder. .

[0073] The terms "inhibition," "inhibitor," or "antagonist" include the term "inhibitor" that refers to an inhibitor that inhibits a given parameter, e.g. This includes reducing the activity of a given molecule or pathway. For example, the kinase being targeted (Raf or The inhibition of MEK activity by 5%, 10%, 20%, 30%, 40% or more was observed using this method. Thus, inhibition can be, but does not have to be, 100%. .

[0074] As used herein, "salt" ("or salts thereof" or "or a salt thereof" means The compound having the formula (I) may be used alone or in combination with a free compound of the present invention. a Raf inhibitor compound, or a Raf inhibitor compound having the formula (II), or a MEK inhibitor; It may preferably be present in admixture with trametinib and is preferably pharma- ceutically acceptable. Such salts include, for example, salts of the compounds of the present invention which have a basic nitrogen atom. from the compounds, preferably as acid addition salts with organic or inorganic acids, in particular as pharma- ceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to a compound that retains the biological effectiveness and properties of the compound. The term "salt" generally refers to salts which are not biologically or otherwise undesirable. Owing to the presence of an amino group, it may be possible to form acid addition salts.

[0075] Lists of suitable salts can be found, for example, in "Remington's Pharmaceutical al Sciences”, 20th ed., Mack Publishing Co. Company, Easton, Pa., (1985) and in the Handbook of Pharmaceutical Salts:Properties,Select tion,and Use”by Stahl and Wermuth(Wiley- VCH, Weinheim, Germany, 2002). .

[0076] For isolation or purification purposes, pharma- ceutically unacceptable salts, such as picrates or perchlorates, may be used. For therapeutic use, it is also possible to use pharma- ceutically acceptable salts or free compounds. are used (where applicable in the form of pharmaceutical preparations) and are therefore preferred. The novel compound in its free form and in its salt form (e.g., purification of the novel compound) and salts which can be used as intermediates in the identification In view of this, any reference to a free compound is also a reference to the corresponding salt, where appropriate. It should be understood that the salts of the compounds used in the combination of the present invention are not intended to be used in pharmaceutical compositions. It is preferable that the salt is a pharma- ceutically acceptable salt that forms a suitable counter ion. are well known in the art. Unless otherwise specified or clearly indicated by the text, Unless otherwise specified, references to therapeutic agents useful in the pharmaceutical combinations provided herein include, but are not limited to, chemical Included are both the free base of the compound and all pharma- ceutically acceptable salts of the compound.

[0077] As used herein, the term "solvate" refers to a compound having variable stoichiometry formed by a solute. (in the present invention, trametinib) or a salt thereof and a solvent complex. The solvent may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, However, water, methanol, and dimethylsulforide Examples of suitable pharma- ceutically acceptable solvents include, but are not limited to, ethanol and acetic acid. Examples of solvents that are not used include water, ethanol and acetic acid.

[0078] As used herein, the term "synergy" refers to the enhancement of the effect of each drug administered by itself. It has an effect that is greater than the sum of the two, for example, delaying the symptomatic progression of cancer or its symptoms. For example, a Raf inhibitor compound having the formula (I) or a pharma- ceutically acceptable salt thereof, M EK inhibitors, preferably trametinib or a pharma- ceutically acceptable salt thereof or a compound of formula (II) or a pharma- ceutically acceptable salt thereof, and a MEK inhibitor, preferably It refers to the action of two drugs, e.g., trametinib or a pharma- ceutical acceptable salt thereof.

[0079] In one embodiment, the combination of the present invention comprises: (a)(i) Formula (I) [ka] or a pharma- ceutically acceptable salt thereof; and (ii) Formula (II) [ka] or a pharma- ceutically acceptable salt thereof; (b) MEK inhibitor and Includes.

[0080] In one embodiment, the combination of the present invention comprises: (a) Raf inhibitors, formula (I) [ka] or a pharma- ceutically acceptable salt thereof; (b) MEK inhibitor and Includes.

[0081] In one embodiment, the combination of the present invention comprises: (a) Raf inhibitors, formula (II) [ka] or a pharma- ceutically acceptable salt thereof; (b) MEK inhibitor and Includes.

[0082] In one embodiment, the combination of the present invention comprises: (a) Raf inhibitors, formula (I) [ka] or a pharma- ceutically acceptable salt thereof; (b) Trametinib, PD0325901, PD184352, refametinib, cobimetinib Tinib, AS-701255, AS-701173, Pimasertib, RDEA436, R MEK inhibitors selected from the group comprising O4987655, RG7167 and RG7420 or a pharma- ceutically acceptable salt or solvate thereof. Includes.

[0083] In one embodiment, the combination of the present invention comprises: (a) Raf inhibitors, formula (II) [ka] or a pharma- ceutically acceptable salt thereof; (b) Trametinib, PD0325901, PD184352, refametinib, cobimetinib Tinib, AS-701255, AS-701173, Pimasertib, RDEA436, R MEK inhibitors selected from the group comprising O4987655, RG7167 and RG7420 or a pharma- ceutically acceptable salt or solvate thereof. Includes.

[0084] In a preferred embodiment, the combination of the present invention comprises (a) Raf inhibitors, (i) Formula (I) [ka] or a pharma- ceutically acceptable salt thereof; and (ii) Formula (II) [ka] or a pharma- ceutically acceptable salt thereof; (b) a MEK inhibitor or trametinib or a pharma- ceutically acceptable salt or solvate thereof Things and Includes.

[0085] In a highly preferred embodiment, the combination of the present invention comprises: (a) Raf inhibitors, formula (I) [ka] or a pharma- ceutically acceptable salt thereof; (b) a MEK inhibitor or trametinib or a pharma- ceutically acceptable salt or solvate thereof (e.g., dimethylsulfoxide solvate) Includes.

[0086] In another preferred embodiment, the combination of the present invention comprises: (a) Raf inhibitors, formula (II) [ka] or a pharma- ceutically acceptable salt thereof; (b) a MEK inhibitor or trametinib or a pharma- ceutically acceptable salt or solvate thereof Things and Includes.

[0087] The combination of the present invention showed no significant improvement in either cell line or human xenograft model, Calu-6. showed enhanced depth and durability of tumor response compared to either monotherapy (see Examples), Therefore, it may be effective in treating proliferative diseases, particularly cancer. mutated tumors, particularly tumors harboring one or more MAPK pathway alterations, e.g., BRAF mutations, K The compounds of formula (I) or their pharma- ceutical acceptable salts for treating RAS-mutated and NRAS-mutated cancers. and a compound of formula (II) or a pharma- ceutically acceptable salt thereof: The Raf inhibitor to be treated is a MEK inhibitor, in particular trametinib or a pharma- ceutically acceptable salt thereof. or a solvate thereof.

[0088] Preferably, these therapeutic agents have therapeutic properties that provide a beneficial effect when combined. The present invention relates to a method for treating proliferative disorders, comprising administering to a subject in need thereof a therapeutically effective amount. The present invention relates to a combination useful for separate, simultaneous or sequential administration to a subject in need thereof. The present invention then particularly relates to the combination of the invention for use in the treatment of proliferative diseases. do.

[0089] Proliferative disorders are multifactorial in nature. In certain circumstances, they have different mechanisms of action. Therapeutic agents may be combined. However, any combination of therapeutic agents having different modes of action is not contemplated. Considering only combinations does not necessarily lead to combinations that have advantageous effects. Not limited.

[0090] In the present invention, administration of the combination of the present invention may, for example, result in increased A more beneficial effect, e.g., synergistic or potentiating effect, in retarding or inhibiting the progression of a reproductive disorder or its symptoms. The above-mentioned antiproliferative effects and possibly further beneficial effects, e.g. fewer side effects, e.g. It is expected that such treatments will result in an improved quality of life or, for example, a reduction in morbidity.

[0091] The combination therapeutic agents of the present invention may be administered separately, simultaneously or sequentially to a subject in need thereof. Preferably, these therapeutic agents are administered in combination to provide benefits. The therapeutically effective dosage is administered to provide a therapeutic effect. The combination of the present invention is for use in the treatment of proliferative diseases, in particular cancer.

[0092] In one embodiment, the proliferative disease is cancer. The term "cancer" is used herein to refer to any cancer, tumor, or tumor. The term is used to refer to a wide range of tumors, including malignancies of the liver, kidney, and blood. The cancer may be locally advanced or metastatic.

[0093] The cancers to be treated by the combination therapy described herein are those that have been treated with standard of care The disease may be progressing in certain settings or for people for whom no effective standard treatment exists.

[0094] Cancers to be treated by the combinations described herein include vemurafenib, BRAF inhibitors such as dabrafenib and / or MAF inhibitors such as cobimetinib and trametinib The cancer may no longer respond to treatment with an EK inhibitor. For example, the cancer may be melanoma, For example, the disease is resistant to treatment with a combination of dabrafenib and trametinib; or BRA that is resistant to treatment with the combination of cobimetinib and vemurafenib The melanoma may be FV600 mutated (including BRAFV600E mutated) melanoma. NSCLC to be treated with the combination described in 0 mutation (including BRAFV600E mutation) NSCLC is treated with BRAF inhibitors such as dabrafenib. Resistant to combination therapy with AF inhibitors and MEK inhibitors such as trametinib could be.

[0095] In one embodiment, the cancer is melanoma, non-small cell lung cancer (NSCLC), MUTYH-associated Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PADC), cervical cancer and ovarian cancer, including lipolysis (MAP) The cancer is selected from the group consisting of fossa cancer.

[0096] In one embodiment, the proliferative disease is non-small cell lung cancer (NSCLC).

[0097] In one embodiment, the proliferative disease is melanoma.

[0098] In one embodiment, the proliferative disorder is colon cancer, including MUTYH-associated polyposis (MAP). (CRC).

[0099] In one embodiment, the proliferative disease is pancreatic ductal adenocarcinoma (PADC).

[0100] In one embodiment, the proliferative disease is cervical cancer.

[0101] In one embodiment, the proliferative disease is ovarian cancer.

[0102] The combination of the present invention is particularly useful in treating one or more of KRAS-mutated and NRAS-mutated tumors. Cancer and related diseases harboring multiple mitogen-activated protein kinase (MAPK) pathway alterations In particular, at least one gain-of-function mutation of Ras as described herein and / or The increased incidence of tumors expressing at least one gain-of-function mutation of Raf as described in the subsection. It is useful in treating reproductive disorders.

[0103] Included are typical or atypical, i.e. BRAFV600E mutations. Regardless of whether the patient has NSCLC or non-BRAF V600E mutant NSCLC, Cancers or tumors with BRAF mutations, including V600D, V600E, V600K, etc. Most patients with NSCLC have at least one V600E or other BRAF mutation. BRAF mutations occur in two regions: the glycine-rich P loop of the N-lobe and the activation segment. The V600E mutation has been detected in a variety of cancers. This is due to a substitution of adenine for thymine at nucleotide 1799. A valine (V) replaced by glutamic acid (E) at donor 600 (now V600 BRAF-mutated melanomas include those with BRAFV600E and Includes BRAFV600D-mutated melanoma.

[0104] Included are KRAS mutant cancers or tumors. The term "KRAS mutant" tumors or cancers include , mutated KRAS proteins, especially gain-of-function KRAS mutations; in particular any G12X, G13X, Q61X, or A146X KRAS mutations (where X is the naturally occurring This includes any tumor that exhibits a nucleotide sequence other than the amino acid sequence present in the nucleotide sequence. For example, a G12V mutation means that glycine is replaced with valine at codon 12. Examples of KRAS mutations in tumors include Q61H, Q61K, G12V, and G12C. , G12D, G12R, G12S, G13D and A146T. KRAS mutant NSCLC has G12X, G13X, Q61X, or A146X. At least one KRAS mutation, particularly Q61K, G12V, G12C, and A146T The cancer includes tumors having at least one KRAS mutation selected from SCLC. It may be early, intermediate or late.

[0105] KRAS mutant cancers include KRAS G12D mutant ovarian cancer; KRAS G12V mutant or G 13D mutation colorectal cancer; KRAS Q61H mutation, KRAS Q61K mutation, KRAS G1 2C-mutated, KRAS G12S-mutated or KRAS G12V-mutated NSCLC; KRAS This includes G12D mutation, G12V mutation, or KRAS G12R mutation pancreatic cancer.

[0106] Included are NRAS mutant cancers or tumors. The term "NRAS mutant" tumors or cancers include Any tumor that exhibits a mutated NRAS protein, especially a gain-of-function NRAS mutation; This includes all G13R, Q61K, Q61L, Q61R, and NRAS mutant tumors. Thus, NRAS-mutated melanomas contain at least one variant corresponding to Q61K, Q61L, or Q61R. The cancer includes melanomas with at least one NRAS mutation. The cancer may be an R-mutated melanoma. The cancer may be early, intermediate or late stage. The cancer may be locally advanced The tumor may be primary or metastatic.

[0107] In one embodiment of the present invention, the cancer is characterized by one or more mutations in B-Raf. can be.

[0108] In another embodiment, the cancer is resistant or refractory to standard treatment.

[0109] In another embodiment, the cancer is resistant to treatment with a B-Raf inhibitor, e.g., dabrafenib. Tolerance or resistance.

[0110] In another embodiment, the cancer is resistant or non-resistant to treatment with a MEK inhibitor, e.g., trametinib. is resistant.

[0111] In another embodiment, the cancer is treated with a B-Raf inhibitor, e.g., dabrafenib and a MEK inhibitor. , for example, are resistant or refractory to treatment with trametinib.

[0112] In one embodiment, the cancer is characterized by at least one gene selected from the group comprising BRAF and KRAS proteins. are characterized by at least one mutation.

[0113] In one embodiment, the cancer comprises BRAF, NRAS, KRAS mutations and combinations thereof. The present invention is characterized by a mutation selected from the group consisting of:

[0114] In one embodiment the combination of the present invention is used in a method for treating a proliferative disease, in particular cancer. Regarding.

[0115] The combination of the present invention is useful in the treatment of KRAS-mutated NSCLC, KRAS-mutated pancreatic cancer, and KRAS-mutated large intestine. It may be particularly useful in treating intestinal cancer or NRAS mutant melanoma. In an embodiment, the proliferative disease or cancer to be treated is KRAS mutant NSCLC. In another preferred embodiment, the proliferative disease or cancer to be treated is a NRAS mutant. It is a heterologous melanoma.

[0116] In one embodiment, provided herein is a method for treating cancer in a subject in need thereof. (a)(i) a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, and (ii) a compound of formula (I) I) or a pharma- ceutically acceptable salt thereof. and (b) a MEK inhibitor. In a preferred embodiment, the MEK inhibitor is trametinib or a derivative thereof. The compound is a physiologically acceptable salt or solvate.

[0117] In one embodiment, provided herein is a method for treating cancer in a subject in need thereof. (a)(i) a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, and (ii) a compound of formula (I) I) or a pharma- ceutically acceptable salt thereof. and (b) a MEK inhibitor, in amounts that are jointly therapeutically effective against said proliferative disease. The combination of the present invention is administered simultaneously, separately or sequentially to a subject in need thereof. In a preferred embodiment, the MEK inhibitor is trametinib or It is a pharma- ceutically acceptable salt or solvate.

[0118] In a further embodiment, the present invention relates to a method for treating, in particular, one or more mitogen-activated proteins. In one embodiment, the present invention relates to a method for treating cancer harboring alterations in the MAPK pathway. The present invention relates to at least one protein selected from the group consisting of BRAS, NRAS and KRAS proteins. In one embodiment, the present invention relates to a method of treating a cancer characterized by at least one mutation in The present invention also relates to the use of a combination according to the invention for the preparation of a medicament for the treatment of a proliferative disease, in particular cancer. In one embodiment, the combination of the present invention relates to the use of It is intended for use in the preparation of

[0119] In a further embodiment, the present invention relates to a method for treating cancer characterized by a gain-of-function mutation in the MAPK pathway. The present invention also relates to the use of a combination according to the invention for the preparation of a medicament for the treatment of a cancer to which it is applied.

[0120] In one embodiment, the combination or composition or both provided herein exhibits a synergistic effect. The results are as follows:

[0121] Thus, in one aspect, the present invention provides a method for treating cancer using an anti-cancer compound in combination with another anti-cancer compound. and in particular (i) a method for enhancing the efficacy of an anti-cancer compound by administering (i) a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and (ii) any of the compounds as defined herein. or a pharma- ceutically acceptable salt thereof, The Raf inhibitor is preferably a MEK inhibitor, suitably trametinib or a pharma- ceutical acceptable salt thereof. or a solvate thereof to provide a similar dose of the compound of formula (I) or a pharma- ceutical or a pharma- ceutically acceptable salt thereof, or a compound (II) or a pharma- ceutically acceptable salt thereof, or a MEK inhibitor. Enhanced efficacy and safety that cannot be safely achieved by administering the drug as a single agent (monotherapy) It is possible to provide a method for providing such an effect.

[0122] A further benefit is that lower doses of the therapeutic agents of the combination of the invention may be used. (For example, this often results in lower dosages as well as use may be less frequent), or side effects observed in one of the combination partners alone It is possible that this could be used to reduce the incidence of side effects that are being treated. consistent with the wishes and requirements of the patient.

[0123] In some embodiments, (i) a compound of formula (I) or (ii) a compound of formula (II) as defined herein, or a pharma- ceutically acceptable salt thereof, A Raf inhibitor compound and / or a MEK inhibitor, preferably trametinib or its A pharma- ceutically acceptable salt or solvate is administered at therapeutic doses or at sub-therapeutic dose levels. In certain embodiments, inhibition, e.g., growth inhibition or tumor inhibition, can be achieved by administering a therapeutic dose to a subject. The concentration or dosage of a given therapeutic agent required to achieve contraction varies depending on the amount of each therapeutic agent administered individually. when another therapeutic agent is used or administered in combination with the first therapeutic agent, rather than when the first therapeutic agent is administered in combination with the first therapeutic agent. In certain embodiments, in combination therapy, inhibition, e.g., growth inhibition, is The concentration or dosage of a given therapeutic agent required to achieve the therapeutic dose as a monotherapy Lower than, for example, 10-20%, 20-30%, 30-40%, 40-50%, 50- 60%, 60-70%, 70-80% or 80-90% lower.

[0124] In determining the synergistic interactions between one or more components, The optimal range and absolute dosage range of each component for efficacy will be provided to the patient in need of treatment. Administration of components over a range of different w / w ratios and doses allows reliable measurement The complexity and expense of conducting human, patient clinical trials make This may make the use of this form of test as a primary model for synergy impractical. However, the observation of synergy in certain experiments (see, for example, Examples 2 and 6) (see, e.g., 2011) may be predictive of efficacy in other species and may be based on existing animal models. The observation of synergy in a species can be further quantified using may be predictive of efficacy in other species, using animal models as described herein. Synergy can be measured using pharmacokinetic / pharmacodynamic Application of PK / PD methods will allow for the determination of effective dose ratio ranges and doses required in other species. It can be used to predict absolute doses and plasma concentrations. The established correlation between the effects seen in humans and the synergistic effects seen in animals, e.g., in heterologous mice, It is suggested that the present invention can be demonstrated by transplantation models or in appropriate cell lines. The combination of these two drugs has been shown to produce the beneficial effects described herein in established test models. Those skilled in the art will be able to demonstrate such beneficial effects in a reasonable test model. The pharmacological activity of the combination of the present invention is, for example, essentially in a clinical trial or in an in vivo or in vitro test procedure as described herein. This can be demonstrated in the

[0125] The combination may be administered in a single formulation or unit dosage form by any suitable route. administration of a combination of drugs, or concurrent but separate administration of the individual drugs in the combination The individual combination parts of the combination of the present invention include sequential administration of the individual drugs. The ner may be administered separately at different times during the course of therapy, or consecutively in any order, or in separate doses. in combination or in parallel in a single combination form, e.g., simultaneously or jointly in therapeutically effective amounts; Preferably, synergistically effective amounts, e.g., daily or intermittent amounts corresponding to the amounts described herein, are administered. Continuous (ie, not daily) dosages can be administered.

[0126] For use in the methods, treatments, combinations and compositions disclosed herein, or a pharma- ceutically acceptable salt thereof, and a compound of formula (II) or a pharma- ceutically acceptable salt thereof The resulting salts are potent inhibitors of BRAF and CRAF. In some embodiments, or a pharma- ceutically acceptable salt thereof or a compound of formula (II) or a pharma- ceutically acceptable salt thereof In one embodiment, the compound of formula (I) or its pharmacopoeitic salts are administered orally. The compound of formula (II) or a pharma- ceutically acceptable salt thereof is 00 mg (e.g., per day). or a pharma- ceutically acceptable salt thereof, Approx. 100mg, Approx. 150mg, Approx. 200mg, Approx. 250mg, Approx. 300mg, Approx. 350m g, about 400mg, about 450mg, about 500mg, about 550mg, about 600mg, about 65 0mg, about 700mg, about 750mg, about 800mg, about 850mg, about 900mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg or about The compound of formula (I) may be administered in a unit dosage of 1200 mg. or a pharma- ceutically acceptable salt thereof, or a compound of formula (II) or a pharma- ceutically acceptable salt thereof. The salt may be administered once a day, twice a day, three times a day, or four times a day. The dosage and timing of administration will depend on the age, weight and sex of the patient; It is determined by criteria such as the extent and severity of the cancer; and the judgment of the treating physician. Preferably, the unit dosage of the compound of formula (I) or the compound of formula (II) is administered once a day. In another preferred embodiment, a unit dose of a compound of formula (I) or a compound of formula (II) is administered twice daily.

[0127] The MEK inhibitor as part of the combination according to the present invention is administered in a therapeutically effective amount to a patient in need thereof. It will be administered to subjects.

[0128] In a preferred embodiment, one of the combinations according to the present invention is administered in a subject in need thereof. The MEK inhibitor trametinib or a pharma- ceutical acceptable salt or salt thereof is administered as a second infusion. The solvate is administered in an amount selected from about 0.125 mg to about 10 mg per day; In some cases, this amount may range from about 0.25 mg to about 9 mg per day; Suitably, this amount will be selected from about 0.25 mg to about 8 mg; suitably, this The amount will be selected from about 0.5 mg to about 8 mg per day; suitably, will be selected from about 0.5 mg to about 7 mg per day; suitably, this amount is The daily dose will be selected from about 1 mg to about 5 mg; suitably, the daily dose will be In a preferred embodiment, trametinib, trametinib or a pharma- ceutically acceptable salt or solvate thereof, the dose being 0.5 mg, 1 mg or It is administered in a daily dose of 2 mg.

[0129] When a dose or dosage is referred to herein, the amount referred to refers to the amount of therapeutic agent. For example, if a 2 mg dose of trametinib is administered, Trametinib is administered in a tablet containing dimethyl sulfoxide, which contains 2 mg trametinib The compound contains trametinib dimethyl sulfoxide equivalent to:

[0130] In some embodiments, trametinib or a pharma- ceutically acceptable salt or solvate thereof. The composition is administered orally. In one embodiment, trametinib is administered via oral delivery. It can be prepared for use in solvated form in dimethylsulfoxide. In some embodiments, the compound is prepared in tablet form for oral administration. The tablets are flexible. The compositions can be prepared in a variety of dosages for a given administration.

[0131] A unit dosage of trametinib or a pharma- ceutically acceptable salt or solvate thereof is administered once daily. It can be administered once a day, twice a day, three times a day, or four times a day. Lametinib or a pharma- ceutically acceptable salt or solvate thereof, such as dimethylsulfoxy The dosolvate can be administered once daily or twice daily.

[0132] For example, as part of a combination therapy, a compound of formula (I) or a pharma- ceutically acceptable salt thereof may be Salt: about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg trametinib may be administered at a total daily dose of about 600 mg, about 600 mg or about 800 mg. For example, a total daily dose of about 1.0 or 2.0 mg in dimethylsulfoxide solvate form The daily dose of the compound of formula (1) can be administered once or twice per day. Thus, a single dose of about 200 mg of the compound of formula (I) can be administered daily. It can be administered twice a day (total daily dose is about 400 mg) at about 1.0 mg or about 2.0 mg. A single dose of about 200 g of trametinib can be administered once per day. mg of a compound of formula (I) administered twice daily (total daily dose of about 400 mg) and a single dose of about 1.0 mg or about 2.0 mg of trametinib per day. Two doses can be administered.

[0133] A compound of formula (I) or a pharma- ceutically acceptable salt thereof and a MEK inhibitor, preferably trametinib. tinib, or a pharma- ceutically acceptable salt or solvate thereof, or a compound of formula (II) or a pharma- ceutically acceptable salt thereof, and a MEK inhibitor, preferably trametinib or a pharmaceutical A commercially available, commercially acceptable salt or solvate of the compound may be used in conjunction with the compound according to the methods disclosed herein. The treatment of the present invention can be administered for 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, It is contemplated that the administration of these two compounds may continue for 4 weeks or longer than 4 weeks. As deemed appropriate by the treating physician, and at further appropriate dosages and frequency of administration. As guided by the methods described herein for determining the intended dosing They can be administered together or separately depending on the amount and frequency of administration. The frequency of administration can vary depending on the dosage used. These may vary depending on the compound being used and the particular condition being treated. The use of the minimum dosage sufficient to provide effective therapy is preferred, and should be determined based on the age of the patient, weight and sex; the extent and severity of the cancer being treated; and the treating physician's judgment. The patient may be generally determined by any of the criteria known to those skilled in the art. The efficacy of the treatment may be monitored using an assay appropriate for the condition being treated. Cut.

[0134] The combination of the present invention (i.e. a compound of formula (I) or a pharma- ceutically acceptable salt thereof and M an EK inhibitor, suitably trametinib, or a pharma- ceutically acceptable salt or solvate thereof; or a compound of formula (II) or a pharma- ceutically acceptable salt thereof and a MEK inhibitor, suitably a trastuzumab The combination of metinib or a pharma- ceutical acceptable salt or solvate thereof with efficacy without toxicity is Optimal ratios, individual and combined dosages and concentrations of combination partners to achieve The kinetics of therapeutic agent availability to the target site and, including but not limited to, the extent of disease progression the age, weight, general health, sex and diet of the individual; the time and route of administration; and the The optimal dosage is based on a variety of factors, including other medications being taken. Certain routine tests and procedures can be used to set up the device. For example, a single bolus can be administered. The dose may be administered in one dose, or in several divided doses administered over time, or the dose may be adjusted according to the urgency of the therapeutic situation. Acute doses can be proportionally decreased or increased as indicated.

[0135] The combination therapeutic agents of the present invention may be administered by any suitable route. The preferred route will depend, for example, on the condition of the recipient of the combination and the cancer being treated. It will be understood that the administration of each of the therapeutic agents may vary depending on the route of administration. and that a therapeutic agent, such as a compound of formula (I) or a pharma- ceutical acceptable salt thereof, may be administered by and a MEK inhibitor, suitably trametinib, or a pharma- ceutically acceptable salt thereof, or or a solvate, or a compound of formula (II) or a pharma- ceutically acceptable salt thereof, and a MEK inhibitor, Suitably, trametinib or a pharma- ceutically acceptable salt or solvate thereof is combined in a pharmaceutical composition. It will be understood that the above-mentioned methods may also be combined together.

[0136] A compound of formula (I) or a pharma- ceutically acceptable salt thereof and a MEK inhibitor, suitably tramethionine. nib, or a pharma- ceutically acceptable salt or solvate thereof, or a compound of formula (II) or and a MEK inhibitor, suitably trametinib or a pharma- ceutical acceptable salt thereof. The salts or solvates thereof may be used together as disclosed herein. The two therapeutic agents of the combination of the present invention may be administered together (simultaneously), sequentially or separately. It is possible.

[0137] Furthermore, it does not matter whether the compounds are administered in the same dosage form; e.g. One compound can be administered topically and the other compound can be administered orally. In this case, both therapeutic agents are administered orally.

[0138] Thus, in one embodiment, one or more doses of a compound of formula (I) or a pharmaceutical agent thereof are administered. or a pharmaceutical composition comprising a compound of formula (II) or a pharmacopoeitic agent thereof. The acceptable salts thereof are administered in combination with one or more doses of a MEK inhibitor, suitably trametinib or its The pharma- ceutically acceptable salts or solvates may be administered simultaneously, sequentially or separately.

[0139] In one embodiment, multiple doses of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, or Repeated doses of the compound of formula (II) or a pharma- ceutically acceptable salt thereof may be administered in the form of repeated doses of ME. K inhibitor, suitably trametinib or a pharma- ceutically acceptable salt or solvate thereof. The two drugs may be administered sequentially or separately.

[0140] In one embodiment, multiple doses of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, or or multiple doses of a compound of formula (II) or a pharma- ceutically acceptable salt thereof, K inhibitor, suitably trametinib or a pharma- ceutically acceptable salt or solvate thereof. The two drugs may be administered sequentially or separately.

[0141] In one embodiment, a single dose of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, or A single dose of a compound of formula (II) or a pharma- ceutically acceptable salt thereof may be administered in the same manner as repeated doses of ME. K inhibitor, suitably trametinib or a pharma- ceutically acceptable salt or solvate thereof. The two drugs may be administered sequentially or separately.

[0142] In one embodiment, a single dose of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, or A single dose of a compound of formula (II) or a pharma- ceutically acceptable salt thereof may be administered in the form of a single dose of ME. K inhibitor, suitably trametinib or a pharma- ceutically acceptable salt or solvate thereof. The two drugs may be administered sequentially or separately.

[0143] In all of the above embodiments, a compound of formula (I) or a pharma- ceutically acceptable salt thereof: or a compound of formula (II) or a pharma- ceutically acceptable salt thereof is administered first, or an EK inhibitor, suitably trametinib or a pharma- ceutically acceptable salt or solvate thereof; may be administered first.

[0144] (i) a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and (ii) a compound of formula (II) or a pharmaceutically acceptable salt thereof. K inhibitor, suitably trametinib or a pharma- ceutically acceptable salt or solvate thereof, It is possible to administer the compound as a raw chemical for use in therapy, but it is also possible to administer the compound as a pharmaceutical composition. It is therefore possible to provide the active ingredient as Provided in the present invention is (a) a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and A Raf inhibitor compound selected from the group consisting of the compounds of formula I) or a pharma- ceutically acceptable salt thereof. and (b) a MEK inhibitor, suitably trametinib or a pharma- ceutically acceptable salt thereof or In one embodiment, the pharmaceutical composition comprises one or more The composition may further comprise a number of pharma- ceutically acceptable diluents, excipients or carriers. The compound is compatible with the other components of the formulation to allow for a pharmaceutical preparation and is suitable for the recipient thereof. The pharmaceutical composition to be utilized must be acceptable in the sense of not being harmful to the human body. These elements may be provided in separate pharmaceutical combinations or together in one pharmaceutical composition. The combinations disclosed herein can be administered together in a single composition. or in two or more different compositions, e.g., in compositions or dosage forms as described. The components may be administered in the same formulation or in separate formulations, e.g., as indicated above. The compounds may be administered as pharmaceutical agents alone or in combination with one or more pharma- ceutical carriers, in any suitable form. It may be administered by any suitable route.

[0145] Dosage unit form as used herein refers to a unitary administration to the subject to be treated. Refers to physically discrete units adapted for dosage; each unit has a desired therapeutic effect. A predetermined amount of an active compound (e.g., a compound of formula (I)) calculated to or a pharma- ceutically acceptable salt thereof, a compound of formula (II) or a pharma- ceutically acceptable salt thereof a salt or a MEK inhibitor, suitably trametinib or a pharma- ceutically acceptable salt or solvent thereof The unit dosage form contains the compound in a fixed combination with the required pharmaceutical carrier. It is also possible.

[0146] The effective dosage of each of the combination partners is compared with the other therapeutic agents in the combination. This may require more frequent administration of one of the therapeutic agents. To enable dosing, the packaged pharmaceutical product contains one or more combinations of compounds. or multiple dosage forms and containing one of the therapeutic agents of the combination of the invention, but The composition may contain one or more dosage forms that do not contain other therapeutic agents.

[0147] The combination partners used in the combination of the present invention may be marketed as single drugs. When applied in a form that is not prescribed, the dosage and mode of administration must be stated otherwise. For example, this may be in accordance with the information provided on the package insert of each marketed drug.

[0148] Therefore, to allow for proper dosing, the packaged pharmaceutical product should contain a combination of drugs. One or more dosage forms containing the combination and one or more dosage forms containing one of the therapeutic agents of the combination but not the combination The combination may contain one or more dosage forms that do not contain any other therapeutic agent.

[0149] Also within the scope of the present invention are compounds that, together with one or more other components, can be used as therapeutic agents. The combinations of the present invention for simultaneous, separate or sequential administration as described herein: instructions for use with the combination of the present invention; other reagents for use with the combination of the present invention; compounds for administration Equipment or other materials for preparing the composition, such as a mixing vessel; a pharma- ceutical acceptable carrier; and The combination kit includes equipment or other materials, such as syringes, for administration to elephants.

[0150] As used herein, the term "combination kit" or "combination kit of components" refers to a combination of components according to the present invention. When both compounds are administered simultaneously, The combination kit may comprise, in a single pharmaceutical composition such as a tablet or in separate pharmaceutical compositions: A compound of formula (I) or a pharma- ceutically acceptable salt thereof and a MEK inhibitor, suitably tramethicone or a pharma- ceutically acceptable salt or solvate thereof, or a compound of formula (II) or a pharma- ceutically acceptable salt and a MEK inhibitor, suitably trametinib or a pharma- ceutically acceptable salt thereof; The compound of formula (I) or its pharma- ceutical salt or solvate may be included. and an acceptable salt thereof, and a MEK inhibitor, suitably trametinib, or a pharma- ceutically acceptable salt thereof. or a solvate thereof, or a compound of formula (II) or a pharma- ceutically acceptable salt thereof, and a pharmacokinetic or pharmacokinetically acceptable salt or solvate thereof, If not administered, the combination kit may be packaged in separate pharmaceutical compositions in a single package or in separate packages. In a separate pharmaceutical composition in the package, a compound of formula (I) or a pharma- ceutically acceptable salt thereof, A compound of formula (II) or a pharma- ceutically acceptable salt thereof and a MEK inhibitor, suitably tramethionine The composition will contain nibs or a pharma- ceutically acceptable salt or solvate thereof.

[0151] In one embodiment of the present invention, the set of components includes: (a)(i) a compound of formula (I): The compound or a pharma- ceutically acceptable salt thereof (including pharma- ceutically acceptable excipients, diluents and / or carriers) together with the body), and (ii) a compound of formula (II) or a pharma- ceutically acceptable salt thereof ( together with an acceptable excipient, diluent and / or carrier) (b) a MEK inhibitor, preferably trametinib or a pharma- ceutically acceptable derivative thereof; a salt or solvate thereof (together with a pharma- ceutically acceptable excipient, diluent or carrier), In some embodiments, these components are provided in a form suitable for sequential, separate and / or simultaneous administration. The combination kit may also be provided with instructions, such as dosage and administration instructions. Instructions for dosage and administration are provided to the physician, for example, by drug product labeling. The type of instruction may be of the type provided by the physician, such as instructions for the patient. It can be something.

[0152] Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. Perhaps.

[0153] The following examples are illustrative of the invention described above. However, these examples are by no means intended to be limiting. The beneficial effects of the pharmaceutical combination of the present invention are , but can also be determined by other test models known per se to the person skilled in the art. EXAMPLES

[0154] The following non-limiting examples are presented to facilitate understanding of the present invention and in no way constitute a limitation thereon. It should not be construed as limiting the scope.

[0155] Example 1: N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridine-4 -yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide The compounds of formula (I) are morpholine-substituted biaryl compounds having the structure: [ka]

[0156] The compounds of formula (I) can be prepared according to the method described in WO 2014 / 15, the contents of which are incorporated by reference. This is Example 1156 in the pamphlet of No. 1616.

[0157] Example 1A The compounds of formula (I) are type II inhibitors of both b-Raf and c-Raf.

[0158] [Table 1]

[0159] Example 1B Compounds of formula (I) inhibit a number of MAPK pathway-expressing mutations, as shown in the following table: The activity is at least partially attributable to the BRAF or RAS kinase activity against human cancer cell lines. It is particularly potent against cell lines harboring one mutation.

[0160] [Table 2]

[0161] Example 1C B-Raf V600 mutant melanocortin resistant to B-Raf and / or MEK inhibitors To examine the activity of the compounds of formula (I) in human ovarian tumor cells, the MEK1 / 2 and NRAS genes were examined. B-Raf V600 melanoma cells expressing aberrant or splice variants of BRAF The antiproliferative activity of the compounds of formula (I) was evaluated in a mechanistic model derived from the strain A375. These mutations have been shown to confer resistance to B-Raf and / or MEK inhibitors in preclinical and clinical studies. This has been demonstrated in both the parental A375 cell line and in mice expressing various mutated genes. Its derivatives include the B-Raf inhibitor vemurafenib and the MEK inhibitor selumetinib. The growth inhibitory effects of the compounds of formula (I) compared to their potency are summarized below. Over 50x IC 50 The effect of both B-Raf and MEK inhibitors on the expression of β-Raf / MEK-dependent agonists was investigated. In contrast, the resistance model was also sensitive to the compound of formula (I). Yes, IC 50 These data suggest that B-Raf and and / or MEK inhibitor-resistant B-Raf V600 melanoma patients The present invention supports the use of compounds of formula (I) in

[0162] [Table 3]

[0163] Example 1D For oral administration, the compound of formula (I) is administered in an amount of about 50 mg according to principles well known in the art. The compound of formula (I) was formulated into tablets containing a sufficient number of tablets to provide the desired dosage. The subjects were administered one tablet per day in a fasting state. The subjects were administered one or two tablets per day at a dose of 100 mg. Patients were treated once daily at a dose of 200 mg. Serial blood samples were collected for pharmacokinetic (PK) evaluation. Fluid samples were collected up to 48 hours after the first administration of a compound of formula (I) (Day 1 of Cycle 1) and then repeatedly. Data were collected up to 24 hours after dosing (Day 15 of Cycle 1). Within 4 hours after administration of a single 100 mg dose and a single 200 mg dose The maximum plasma concentrations (Cmax) of 447 ng / ml and 889 ng / ml were obtained, respectively. The mean plasma exposure (AUCtau) over the 24-hour dosing interval on the first day of dosing was: 5679 hr.ng / m after administration of 100 mg and 200 mg of the compound of formula (I), respectively. The half-life was approximately 23-24 h in patients. A once-daily dose of 100 mg is calculated to result in a cumulative rate of 1.8 in the blood. Based on these data, the 1 day A once per day dosing schedule was established.

[0164] Example 2: Antitumor activity of compounds of formula (I) in KRAS-mutated NSCLC models In cell-based assays, compounds of formula (I) activate MAPK signaling For example, compounds of formula (I) have been shown to have antiproliferative activity in cell lines containing various mutations that The compounds inhibited the non-small cell lung cancer cell line Calu-6 (KR) with IC50 values ​​ranging from 0.2 to 1.2 μM. inhibited the proliferation of the colon cell line HCT116 (KRAS G13D) and the IL-111 (KRAS Q61K) .

[0165] The activity of compounds of formula (I) was tested in vivo in several xenograft models. As shown in Tables 1-4, the compounds of formula (I) exhibit single agent activity in KRAS mutant lung cancer models. did.

[0166] Calu6 model (KRAS(Q61K) mutant NSCLC): Tumor-bearing female Calu6 nude mice (n=8 / group) were cultured at 100°C for 12 h at 4°C until the mean tumor volume reached 324 m. m3. On the 15th day after xenograft implantation, the compound of formula (I) was administered. The animals were administered 10 ml / kg (animal body weight) of 100 mg ... In terms of dosage, 15 mg / kg twice daily (bid), 30 mg / kg twice daily (bid) for 13 consecutive days kg once daily (qd), 50 mg / kg bid, 100 mg / kg bid, 200 mg / kg qd or 300 mg / kg every other day (q2d) oral dose of vehicle, (I) compound was administered. Tumor volumes were measured at the time of randomization using digital calipers. , and twice weekly thereafter for the duration of the study (Figure 1). kg qd (4% body weight loss) and 300 mg / kg q2d (9% body weight loss) treatment groups. It was recognized that

[0167] H358 model (KRAS(G12C) mutated NSCLC): Tumor-bearing female SCID beige NCI-H358 mice (n=8 / group) were cultured at 100°C for 1 h at 1 h. The tumor volume range was 261 mm 3 Fourteen days after tumor cell inoculation, the subjects were randomly divided into three groups. .

[0168] Animals received successive doses of 10 ml / kg (animal body weight) throughout the course of treatment. The subjects were given oral doses of vehicle, formula (II) and 200 mg / kg (daily) for 14 days. The tumor volumes were measured three times a week by digital calipers and were Body weights of all animals were recorded throughout the study (Figure 2). 0.05 mg / kg (4% weight loss) and 200 mg / kg (6% weight loss) treatment groups.

[0169] PTX model HLUX1156-KRAS(G12C) mutant NSCLC: The first lung cancer xenograft, HLUX1156 (n= 10) derived from a patient with a tumor in female nude mice 6 / group) were randomly divided into two groups with a mean tumor volume range of 262 mm3. Treatment was initiated 38 days after graft implantation. Animals received 10 ml / kg ( Oral administration at 100 mg / kg (daily) for 14 consecutive days in a dosage volume of 100 mg / kg (animal body weight) Each mouse was administered a single dose of vehicle or a compound of formula (I). Tumor volumes were measured weekly using digital calipers. Body weights of all animals were measured twice and recorded throughout the course of treatment (Figure 3). The treatment was well tolerated as judged by the absence of significant weight loss.

[0170] H727 model - KRAS(G12V) mutated NSCLC: Tumor-bearing Foxn1 female nude mice NCI-H727 (n=8 / group) were cultured at 100x the mean tumor size. The patients were randomly divided into two groups with tumor volumes ranging from 275 mm3 to 275 mm3. Day 21 after xenograft implantation Treatment was started on the eyes. Animals received 10 ml / kg (animal body weight) of the drug solution for the duration of the course of treatment. The subjects were administered an oral dose of vehicle or the formula at 100 mg / kg (daily) for 14 consecutive days. Compound (I) was administered. Tumor volumes were measured three times a week by digital calipers and were The weights of all animals were recorded throughout the course (Figure 4). / kg (4.5% body weight loss) was observed in the treatment group.

[0171] Antitumor activity was measured as tumor volume in the treated group versus the vehicle-treated group. (% T / C) or the percentage of tumor regression compared to the starting volume (% Regression) In vivo, treatment with the compound of formula (I) inhibited the proliferation of NSCLC-derived C Includes alu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C) It led to tumor regression in several KRAS mutant models. In all cases, The antitumor effect was dose-dependent. The Calu-6 model showed that the compound of formula (I) The drug was sensitive to 50 mg / kg and 100 mg / kg twice daily (BID) in mice. ), and 100 and 200 mg / kg QD, and 300 mg / kg Tumor regression was observed at doses of 200 mg / kg once every other day (Q2D). QD dosing was also achieved in a second human NSCLC model, NCI-H358. ,Data from a dose-fractionated efficacy study in Calu-6 xenografts show that ,tRNA is administered QD and Compounds of formula (I) administered twice daily (BID) showed similar efficacy across a range of dosage levels. These results demonstrate that QDs or B have antitumor activity at levels similar to those of β-blockers in the clinic. Facilitate review of ID dosing regimens.

[0172] In summary, the in vitro efficacy observed for well tolerated doses of the compound of formula (I) is The MAPK pathway inhibitory and antiproliferative activity in vivo and in vivo demonstrate that the compounds of formula (I) inhibit the MAPK pathway. It may have antitumor activity in patients with tumors that have underlying activation damage in the tract. and therefore specifically as single agents or as inhibitors that affect different steps of the MAPK pathway. For the treatment of patients with NSCLC harboring KRAS mutations, in combination with a second agent such as It is suggested that the compounds of formula (I) may be useful in treating ovarian cancer, pancreatic cancer and melanoma. These include those expressing gain-of-function mutations in the MAPK pathway, e.g., RAS or RAF. It has been shown to have activity as a single agent against a variety of other cancers.

[0173] Example 2: Synergistic effect of the combination of the compound of formula (I) with trametinib on cell growth NRAS mutant melanoma, KRAS mutant NSCLC, KRAS mutant PDAC and KRA Compound of formula (I) and MEK1 / 2 on proliferation and signaling in S-mutated CRC The effect of combining with the inhibitor trametinib was tested as follows.

[0174] CellTiter-Glo® (CTG) Luminescent Cell Viability Assay Kit (P romega, Madison, WI, USA) is present in the wells after cell lysis. The amount of ATP is measured. The ATP released upon lysis reacts with luciferase and its substrate luciferase. The amount of light emitted is proportional to the amount of ATP. This is in turn proportional to the number of live cells in the well. This assay can be used to measure the number of cells in the well after drug treatment. The percentage of viable cells is determined.

[0175] NRAS mutant melanoma cell lines and KRAS mutant NSCLC cell lines were maintained in appropriate culture media. I held it.

[0176] [Table 4]

[0177] For NRAS mutant melanoma lines, the compound of formula (I) was administered in the range of 0.002 to 10 μM. The whole grid was analyzed using the sera concentration and trametinib concentrations ranging from 1.52E-4 to 1 μM. The combinations were evaluated in the matrix. For KRAS mutant NSCLC lines, the The compound of formula (I) concentrations ranged from 0.004 to 2.7 μM. The nib concentration is used to construct the matrix in a full grid or in a checkerboard matrix. We evaluated combinations of 100 and 150 mAbs in a given cell line to determine whether the combination was synergistic. The score for inhibition (SS) and the 50 percent inhibition (CI 50 ) Combination index for effect size The CI was determined using the CI (Lehar et al., 2009). A summary of these values ​​for each is given in the table below.

[0178] [Table 5]

[0179] This study was repeated using KRAS mutant PDAC and CRC models with the following results: obtained.

[0180] [Table 6]

[0181] General guidelines for interpretation of the scores / values ​​are provided in the table below.

[0182] [Table 7]

[0183] As shown in the above table, the compound of formula (I) and trametinib inhibit KRAS and NR The compound of formula (I) and Trametinib have a synergistic effect on cell growth in AS mutant cell lines. Combining it with tinib produced moderate to high efficacy results in all but one cell line tested. The effect was synergistic to the maximum extent. Non-synergistic / additive effect was observed in one NSCLC cell line, N In CI-H2030, monotherapy with either the compound of formula (I) or trametinib was performed. The lack of observed response is due to the fact that this model is not MAPK dependent. Very likely.

[0184] The combination of the compound of formula (I) with trametinib was shown to be effective in treating all NRAs tested. Intermediate in S-mutated melanoma cells, KRAS-mutated PDAC, and KRAS-mutated CRC lines The combination of the compound of formula (I) with trametinib was synergistic in potency. Moderate to strong association in 14 of 15 KRAS-mutated NSCLC cell lines tested It was exponential.

[0185] NCI-1 showed the strongest synergy among KRAS-mutated NSCLC lines tested In the H2122 example, the Loewe excess grid is based on the Loewe dose additive model and the low dose Amounts of the compound of formula (I) and trametinib (0.041-0.37 μM compound of formula (I) and 0.11 μM trametinib). At these low doses, the compound of formula (I) as a single agent exhibited maximum inhibition values ​​of <30 at doses below 1 μM. %, but has little or no activity against tramethicone at the same dose of the compound of formula (I). The combination with Nib has significant synergy (>40% Loewe excess).

[0186] It had the strongest synergistic effect among all NRAS melanoma cell lines tested. In the SK-MEL-2 model, both low doses of trametinib and the compound of formula (I) (0.0 0.02 to 0.371 μM of the compound of formula (I) and 0.000152 to 0.001 μM of Tramembrane There is significant synergy with the two lowest doses of trametinib (0.000 152-0.000457 μM trametinib), and the range of 0.014-0.124 μM There is strong synergy with doses of the compound of formula (I) in the range of 0.1 to 100 mg / kg / day, with little or no single agent activity. The antiproliferative effects are achieved at concentrations that are not tolerated.

[0187] Pharmacodynamics of the compound of formula (I) and trametinib in KRAS and NRAS mutant cell lines Inhibits target biomarkers The synergistic antiproliferative effect of combining the compound of formula (I) with trametinib is due to To explore the mechanism by which this combination works, we investigated the effect of this combination on MAPK signaling in Western blots. The cells were treated with the compound of formula (I) (300 nM) alone or in combination with a transmembrane blot assay. Treatment with metinib (3 nM) was performed for 4 or 24 hours. As a further comparison, cells were also treated with a 10-fold higher single dose of the compound of formula (I) and a trastuzumab. Treatment with metinib was performed at 3000 nM and 30 nM, respectively.

[0188] NRAS mutant melanoma cell lines (IPC-298 and MM415) and KRAs tested In both S mutant NSCLC (NCI-H23 and NCI-H358) cell lines, Treatment of cells with the combination of compound (I) and trametinib showed that the p by suppressing MEK1 / 2 and pERK1 / 2 levels more potently than either single agent treatment As judged, it was superior to either single agent alone in inhibiting the pathway. The inhibition produced by the dose combination was 10-fold higher than that achieved by the compound of formula (I). This is superior to what can be obtained and is consistent with that observed at higher trametinib levels. , but with slightly lower robustness. Thus, the compound of formula (I) and trametinib The combination treatment resulted in highly synergistic inhibition of MAPK signaling.

[0189] Example 3: In vivo antitumor activity of the combination of the compound of formula (I) with trametinib. As described below, combination treatment of a compound of formula (I) with trametinib inhibits human KR In xenograft models of NRAS-mutated NSCLC, CRC, PDAC, and NRAS-mutated melanoma, was found to result in greater depth and durability of tumor responses compared to either agent alone Thus, the combined activity of the compound of formula (I) and trametinib is consistent with that the cancer is Greater and more durable responses achieved in patients with an activated MAPK pathway It is highly likely that they will.

[0190] Combination of Compounds of Formula (I) with MEK Inhibitors in KRAS Mutant NSCLC Cancer Models Antitumor activity of Synthesis of Formula (I) in Calu-6 NSCLC Tumors, a KRAS Mutant NSCLC Model The antitumor activity of the compound in combination with a MEK inhibitor was established in female nude mice. The tumor is approximately 250 mm 3 Once tumor volume reached 0.01, mice were randomized into treatment groups (n Treatment was initiated 10 days after xenograft implantation. Antitumor activity was evaluated by comparing the tumor cell The time was determined to be 27 days after cell transplantation; 17 days after the start of treatment.

[0191] The test drugs were administered in a dose volume of 10 ml / kg (animal body weight) throughout the course of treatment. and 6 orally once daily (qd) or once every other day (q2d) at the dose levels indicated. The single agent was administered for 28 days, and the combination of the compound of formula (I) and trametinib was Tumor volumes were measured twice weekly by digital caliper and were Body weights of all animals were recorded throughout.

[0192] Antitumor activity, mean change in tumor volume, mean change in body weight (percentage) and time from start of treatment Survival after 17 days (27 days after transplant) is reported in the table below.

[0193] [Table 8]

[0194] After 17 days of dosing, the compound of formula (I) administered at 30 mg / kg qd showed a 26% T / C was achieved with 0.3 mg / kg qd or 0.3 mg / kg q2d Trametinib achieved 36% and 53% T / C, respectively. Seven days later, the compound of formula (I) administered at 30 mg / kg qd was replaced by a compound of formula (I) administered at 0.3 mg / kg qd Combining it with trametinib administered at 0.3 mg / kg q2d or 0.3 mg / kg q2d The regression rates were 41% and 13%, respectively (Figure 5).

[0195] To quantitatively evaluate the time to progression between groups, the tumor volume was 700 mm 3 The option The day on which the cut-off was exceeded was recorded. The combination with metinib demonstrated increased and statistically significant antitumor activity compared to single agents. Tumors in mice treated with the compound of formula (I) and trametinib as single agents were progressed during treatment, whereas the combination of the compound of formula (I) and trametinib Tumor regression lasts longer than monotherapy - 28 days after dosing (tumor 38 days after implantation), had significant antitumor activity.

[0196] All treatment groups were also well tolerated with minimal weight loss over the course of the study. The combination of the compound of formula (I) with trametinib also increased the reaction depth in addition to This resulted in increased persistence of the response (Table below and Figure 6).

[0197] [Table 9]

[0198] Antibody Combination of Compound of Formula (I) with MEK Inhibitors in KRAS Mutant Colon Cancer Models Tumor activity HCT116 (KRAS G13D) colorectal cancer (CRC) tumors were cultured in female nude mice. The tumor was approximately 230 mm 3 Once tumor volume reached 100 μg / kg, mice were randomized according to tumor volume. The treatment was started on the 14th day after xenograft transplantation. Gender was determined on day 31 after tumor cell implantation (the last day for vehicle-treated mice).

[0199] The test drugs were administered in a dose volume of 10 ml / kg (animal body weight) during the course of treatment. Orally once daily (qd) or once every other day (q2d) at the dose levels shown in 6(A). Tumor volumes were measured twice weekly by digital caliper and were maintained throughout the course of treatment. After 17 days of dosing, the animals were dosed at 100 mg / kg qd and the body weights of all animals were recorded. The compound of formula (I) achieved 30% T / C, whereas at 0.3 mg / kg qd Trametinib administered at 100 mg / kg achieved a T / C of 44%. Compound of formula (I) administered at 0.3 mg / kg qd was compared with a compound of formula (I) administered at 0.3 mg / kg q2d. Combining it with lametinib achieved a 26% regression (Figure 16). On day 4, one mouse was sacrificed due to increasing weight loss. On day 31, the final day of vehicle treatment, On day 1, mice treated with the compound of formula (I) had a combined weight loss of 4%; Mice treated with trametinib exhibited a 3.5% weight loss, whereas the compound of formula (I) and trametinib Mice treated with the combination showed a 9% weight loss.

[0200] Antitumor Activity of the Combination of Compound of Formula (I) with MEK Inhibitors in PDAC Cancer Models 2043 patient-derived PDAC (KRAS G12D ) Tumors were grown in female nude mice. The tumor was approximately 230 mm 3 Once tumor volume reached 100 μg / kg, mice were randomized according to tumor volume. Treatment was initiated 52 days after xenograft implantation. Antitumor activity was determined on day 73 after tumor cell implantation.

[0201] The test drugs were administered in a dose volume of 10 ml / kg (animal body weight) during the course of treatment. Administered orally once daily (qd) or once every other day (q2d) at the dose levels shown in 7A. Tumor volumes were measured twice weekly by digital caliper and were maintained throughout the course of treatment. The body weights of all animals were recorded. After 21 days of dosing, the formula was administered at 100 mg / kg qd. Compound (I) achieved 55% T / C, whereas when administered at 0.3 mg / kg qd. Trametinib administered at 100 mg / kg achieved a T / C of 32%. Compound of formula (I) administered qd at 0.3 mg / kg q2d Combining it with tinib achieved 35% regression (Figure 17). Day 66 after tumor implantation One mouse was sacrificed due to increasing weight loss. Day 73, last day of combination treatment In contrast, mice treated with the compound of formula I had a combined weight loss of 0.6%; Mice treated with trametinib exhibited a 0.3% weight loss, and the combination of the compound of formula I with trametinib Mice treated with the combination showed a 9.6% weight loss.

[0202] Antitumor activity of the combination of the compound of formula (I) with a MEK inhibitor in a melanoma cancer model sex Compound of formula (I) and MEK in several human NRAS mutant melanoma xenografts The antitumor activity of combinations with inhibitors was studied as follows.

[0203] (i) SKMEL30 melanoma model SKMEL30(NRAS Q61K ) Melanoma tumors were established in female nude mice. Treatments were administered at a dose volume of 10 mL / kg. On day 12 after tumor implantation, the mean tumor volume was When the tumor volume reached 190 mm3, mice were randomized into treatment groups (n=9). Gender was determined 34 days after tumor cell implantation; 22 days after initiation of treatment.

[0204] The test drugs were administered in a dose volume of 10 ml / kg (animal body weight) during the course of treatment. The dose levels shown in Table 8 were administered orally once daily (qd) or twice daily (bid). Tumor volumes were measured twice weekly by digital caliper and were included in all 116 patients throughout the course of treatment. The body weights of the animals were recorded. On day 34, the final day that the vehicle-treated group was studied, Treatment with this compound resulted in 5% tumor regression, whereas treatment with 0.3 mg / kg qd Lametinib resulted in 8% T / C. Compound of formula (I) and 0.15 mg / kg The combination with trametinib qd reduced tumor size by 48% compared to the vehicle-treated group. The results showed a further increase in antitumor activity with tumor regression (Figure 18). The drug was well tolerated, with minimal weight loss during the study. In the combination group of the compound of formula I and trametinib, A short drug holiday (days 28 to 31) was given, after which the complete group was administered until the end of the study. The combination was continued again.

[0205] (ii) NRAS mutant melanoma model 20667 Patient-derived “20667” (NRAS Q61R ) melanoma tumors in female nude mice The tumor was approximately 300 mm 3 Once tumor volume was reached, mice were randomly sorted according to tumor volume. Patients were randomly assigned to treatment groups (n=7). Treatment was initiated on day 17 after xenograft transplantation. The antitumor activity of the compound of formula (I) was determined on the 34th day after tumor cell implantation. The antitumor activity of the combination with trametinib was determined 48 days after tumor cell implantation.

[0206] The test drugs were administered in a dose volume of 10 ml / kg (animal body weight) during the course of treatment. The subjects were administered orally once daily (qd) or twice daily (bid) at the dose levels indicated in Table 9. Tumor volumes were measured twice weekly by digital caliper and were included in all 116 patients throughout the course of treatment. The body weight of the animals was recorded. After 17 days of dosing, the compound of formula (I) administered at 100 mg / kg qd The compound achieved 87% T / C, whereas the T / C administered at 0.3 mg / kg qd Lametinib achieved an 82% T / C after 31 days of dosing at 50 mg / kg bid. Compound of formula (I) administered at 0.3 mg / kg qd was combined with trametinib administered at 0.3 mg / kg qd. The combination achieved 68% regression (Figure 19). All treatment groups achieved The treatment was well tolerated with minimal weight loss.

[0207] (iii) NRAS mutant melanoma model 21124 Patient-derived “21124” (NRAS Q61H ) melanoma tumors in female nude mice The tumor was approximately 300 mm3 Once tumor volume was reached, mice were randomly sorted according to tumor volume. Patients were randomly assigned to treatment groups (n=5). Treatment was initiated 45 days after xenograft transplantation. Tumor activity was determined 66 days after tumor cell implantation.

[0208] The test drugs were administered in a dose volume of 10 ml / kg (animal body weight) during the course of treatment. Dose levels indicated were administered orally once daily (qd) or twice daily (bid). Tumor volumes were measured twice weekly by digital caliper and were included in all 116 patients throughout the course of treatment. The body weight of the animals was recorded. After 17 days of dosing, the compound of formula (I) administered at 100 mg / kg qd The compound achieved 10% T / C, whereas T / C administered at 0.3 mg / kg qd Lametinib achieved a 54% T / C after 21 days of dosing at 50 mg / kg bid. The compound of formula (I) administered was trametinib administered at 0.0375 mg / kg qd. Combining the treatment with cyclophosphamide achieved 40% regression (Figure 20). All treatment groups were There was no weight loss during the treatment and it was well tolerated.)

[0209] (iv) NRAS mutant melanoma model "20864" Patient-derived “21124” (NRAS Q61H ) melanoma tumors in female nude mice The tumor was approximately 300 mm 3 Once tumor volume was reached, mice were randomly sorted according to tumor volume. Patients were randomly assigned to treatment groups (n=5). Treatment was initiated on day 19 after xenograft transplantation. The antitumor activity of the compound of formula (I) was determined on the 33rd day after tumor cell implantation. The antitumor activity of the combination with trametinib was determined 55 days after tumor cell implantation.

[0210] The test drugs were administered in a dose volume of 10 ml / kg (animal body weight) during the course of treatment. The dose levels shown in Table 1 were administered orally once daily (qd) or twice daily (bid). Tumor volumes were measured twice weekly by digital caliper and were included in all 116 patients throughout the course of treatment. The body weight of the animals was recorded. After 14 days of dosing, the compound of formula (I) administered at 50 mg / kg bid was The compound achieved 30% T / C, whereas the T / C administered at 0.3 mg / kg qd Lametinib achieved an 84% T / C after 36 days of dosing at 50 mg / kg bid. The compound of formula (I) administered was trametinib administered at 0.0375 mg / kg qd. Combining the treatment with ribosomes achieved 12% regression (Figure 21). Two mice were sacrificed for the pharmacodynamic study. For the remaining studies, efficacy was evaluated with n=3. All treatment groups were well tolerated with minimal weight loss over the course of the study. showed.

[0211] In summary, the data show that combination treatment with the compound of formula (I) and trametinib is effective in preventing MA In patients with an activated MAPK pathway caused by gain-of-function mutations in the PK pathway, These results suggest that it may be possible to achieve greater and more durable responses with Some of the combinations showed slight weight loss (up to 10%), but none of the combinations tested The majority of combination doses were well tolerated as judged by minimal weight loss. .

[0212] Example 3: Single-cell tumor recurrence in adult patients with advanced solid tumors harboring MAPK pathway alterations Phase I study of the compound of formula (I) in combination with trametinib and cefotaxime The recommended starting dose and regimen for the compound of formula (I) as a single agent in this study is , preclinical safety, tolerability data, pharmacokinetics (PK) and / or pharmacodynamics in preclinical studies PD data as well as potential side effects while limiting the number of patients who may receive an inactive dose. Preliminary human effective dose ranges to minimize exposure to potentially toxic drug levels Based on projections, 100 mg orally once daily (QD).

[0213] Starting doses of 100 mg, 200 mg, 250 mg, 300 mg or 400 mg are envisaged. Preliminary data suggest a starting dose of 250 mg once daily (QD) for solid tumors. For maximum dosing versatility, the compounds of formula (I) may be administered orally. It can be prepared as 50 mg and / or 100 mg tablets for preclinical studies. It has been demonstrated that the QD regimen is effective and well tolerated. In transplantation, similar levels of efficacy were observed using QD or divided twice-daily (BID) regimens. was obtained, suggesting that efficacy is related to total exposure. The K and predicted half-life (~9 h) also suggest that effective exposure can be achieved with QD dosing. do.

[0214] Dose escalation of a compound of formula (I) in combination with a MEK inhibitor, such as trametinib, is The patient will begin with a dosing regimen in which the compound of formula (I) is identified as a single agent. The starting dose of the combination may be lower than the doses of the single agents. Thus, the choice of dose depends on: while limiting the number of patients who may receive doses that are too low to provide superior efficacy. Exposure to potentially toxic drug levels should be minimized. MEK inhibitors, e.g. Lametinib will be administered at a fixed dose of 2 mg, the recommended single-agent dosage. .

[0215] In the dose expansion part, patients in the combination arm will receive Treatment will be at the dose and regimen recommended for the combination.

[0216] Combination studies included a daily dose of 400 mg of the compound of formula (I) (QD) and a daily dose of or a daily dose of 400 mg of a compound of formula (I) and a daily dose of 2 It is envisaged that the daily dose of the compound of formula (I) is administered once daily. It can be administered twice daily preferentially to the daily dose of trametinib. Other doses, e.g. For example, the doses in the table below can also be administered.

[0217] [Table 10]

[0218] In addition, effective dosing should be determined by monitoring biomarkers indicative of MAP kinase pathway inhibition. Specifically, the dual specificity phosphatase 6 (DUSP6) can be determined by DUSP6 is a known biomarker for this pathway, and in vivo levels of DUSP6 The patient receives a dosage of the compound of formula (I) that provides an effective plasma concentration of the compound of formula (I). It has been shown that DUSP6 reduces the inflammatory bowel disease in subjects with In subjects treated with a compound of formula (I) with or without a MEK inhibitor These drugs can be used as pharmacodynamic biomarkers.

[0219] Example 4: N-(2-methyl-5'-morpholino-6'-((tetrahydro-2H-pyra) (4-yl)oxy)-[3,3'-bipyridine]-5-yl)-3-(trifluoro Methyl)benzamide The compound of formula (II) is a morpholine-substituted biaryl compound having the structure: [ka]

[0220] The compound of formula (II) is an inhibitor of B-Raf and C-Raf. The preparation of which is described in PCT Patent Application WO 2014 / 151616. This is described in Example 131 in the publication.

[0221] Example 4A The compounds of formula (II) inhibit type II agonists of both mutant and wild-type B-Raf and C-Raf. It is an inhibitor.

[0222] [Table 11]

[0223] Example 4B The compounds of formula (II) have been shown to inhibit multiple inflammatory cytokines that express mutations in the MAPK pathway, as shown in the following table: The activity of these antibodies is consistent with that of the antibodies shown to inhibit at least one of the BRAF or RAS receptors. It is particularly potent against cell lines harboring one or more endogenous mutations.

[0224] [Table 12]

[0225] Example 4C of formula (II) in cell lines harboring BRAFV600, NRAS or KRAS mutations The activity of the compound and dabrafenib was compared (Figure 7). Both the amide and the compound of formula (II) almost completely inhibited the ME at 0.05 and 0.5 μM, respectively. In contrast, the three endothelial cells harboring NRAS or KRAS mutations inhibited K and ERK phosphorylation. In these cell lines, dabrafenib treatment at 0.05 and 0.5 μM inhibited the MEK and ERK ligands. In comparison, the compound of formula (II) showed increased phosphorylation and only modest inhibition at 5 μM. The compound inhibited M without apparent pathway activation in all three RAS mutant models. Dose-dependent inhibition of ERK and ERK phosphorylation (p in IPC-298 and HCT116 The compound of formula (II) inhibited the signal transduction pathway (minimal activation of MEK) (Figure 7). The ability to inhibit BRAF V600 mutations in cells harboring various RAS mutations The results were comparable across all the groups, with almost complete inhibition of pMEK and pERK achieved at 0.5 μM. Reached.

[0226] The antiproliferative activity of the compound of formula (II) and dabrafenib in these cell lines was also investigated. (Figure 8). Consistent with the signaling data, dabrafenib inhibited BRAF V600E A3 The most potent antiproliferative activity (IC 50 =0.003μM), NRAS mut Approximately 100x weaker in IPC-298 cells (IC 50 =0.27μM), and two KRAS mut Cell line (Calu-6 IC 50 =23μM, HCT116 IC 50 = 17 μM). In contrast, compound of formula (II) BRAF mut Compared with the model, RASmut Smaller IC in model 50 dose The results showed that the IC 50 The values ​​were 0.01 for A375, IPC-298, Calu-6 and HCT116, respectively. 13 μM, 0.07 μM, 1.4 μM and 0.98 μM.

[0227] Similar experiments using compounds of formula (I) have shown that compounds of formula (I) give similar results. It has also been demonstrated (see table below).

[0228] [Table 13]

[0229] These data demonstrate that the compounds of formula (I) and (II) are RAF monomer inhibitors. We demonstrate that RAF exhibits classes and modes of inhibition that are distinct from RAF dimers. Its inhibitory activity is unlikely to be effective in RAS-mutated tumors. In contrast to nibs, no studies have shown efficacy in treating tumors harboring BRAF or RAS mutations. This suggests that

[0230] Example 4D The antiproliferative activity of compounds of formula (II) was evaluated in a wide range of genetically characterized human cancer cell line models. The panel included BRAF, KRAS, or NRAS mutations. In 357 cell lines or wild type for both BRAF and RAS, The activity of this compound was compared to that of dabrafenib (Figure 9). Each data point represents 3 days of treatment. The inhibitor IC50 values ​​in the cell lines after incubation are shown. The inhibitor IC50 of 5 μM was used as the cutoff. Sensitive (IC50<5μM) and insensitive (IC50>5μM) strains were used as controls. The number of genetic groups is shown for the compound of formula (II) and dabrafenib. For example, the compounds of formula (II) inhibit non-V6 A cancer cell line harboring the KRAS 00 mutation (ovarian cancer cell line Hey-A8 (KRAS G12D / BRAF G464E ,I C 50 =0.63μM), breast cancer cell line MDA-MB-231 (KRAS G 13D / BRAF G464V ,I C 50 = 3.4 μM) and lung cancer cell line NCI-H166 6(BRAF G466V ,I C 50 = 3.97 μM) In comparison, the BRAF monomeric inhibitor dabrafenib inhibited BRAF expression in all three cell line models. In IC 50 The data were analyzed using Fisher's exact test. The sensitivity of mutant cell lines to inhibitor treatment was compared with that of wild-type cell lines. For the compound of formula (II), B-Raf was significantly increased. In contrast, cell lines harboring KRAS or N-Ras mutations showed significantly reduced expression of IFN-γ compared to wild-type cells. The results showed a significantly increased sensitivity, with p values ​​of 3.09 × 10 -17 , 1.19×10 - 4 and 1.26 x 10 -6 The odds ratios were 28.9, 4.6, and 10. In comparison, higher sensitivity to dabrafenib was seen in patients with KRAS or NRAS mutations. The results were significant only in cell lines harboring B-Raf mutations without as mutations, with p values ​​of 1.9×10 each -15 , 0.11 and 0.25.

[0231] Example 5: Antitumor activity of the compound of formula (II) in KRAS mutated NSCLC models Both the signal transduction inhibition and the antitumor efficacy of the compound of formula (II) were observed in the KRAS mutant Calu The study was carried out in vivo in the Calu-6 tumor model. Rigel (trademark) cells were injected subcutaneously into the right flank of female nude mice (6-8 weeks old). Tumor-bearing mice were randomly assigned to treatment groups and Treatment with a single oral dose of a compound of formula (II) over a range of doses (10-200 mg / kg) The tumor tissue was then transferred to the MesoScale Discovery (MSD) platform. Phospholipase C (PcC) was detected using DUSP6 mRNA by quantitative PCR (qPCR) or Levels of MEK1 / 2 in the IL-1 and IL-2 complexes were collected at multiple time points after dosing. As shown in FIG. Treatment with compounds of formula (II) inhibits MEK in a dose-dependent manner, both in extent and duration. The compound of formula (II) at 100 mg / kg and 200 mg / kg resulted in inhibition of phosphorylation. In both the 100 and 150 kg mice, phosphorylated MEK (pMEK) was increased by more than 50% in 16 h. The compound of formula (II) was then used in the same tumor xenograft model to inhibit the tumor growth rate for a long time. The antitumor efficacy of the compound was evaluated (Figure 11). Tumor-bearing animals were dosed with 10, 30, 100 or 2 Vehicle, a compound of formula (II) administered orally at 0.00 mg / kg daily (qd) for 19 days Antitumor activity was evaluated as the ratio of tumor volume in the treated group to that in the vehicle-treated group. The percentage of tumor volume in the initial stage (% T / C) or the percentage of tumor regression compared to the initial volume (regression ( Tumor volumes and body weights were determined at the time of randomization and at 1 h post-randomization. The tumor volumes were determined by caliper measurements and calculated using a modified ellipsoid model. (where, tumor volume (TV) (mm 3 )=[((l×w2)×3.14159)) / 6] where l is the longest axis of the tumor and w is perpendicular to l) Consistent with pMEK inhibition, treatment with the compound of formula (II) increased the The compound produced dose-dependent antitumor activity starting at 30 mg / kg ( FIG. 11 ). Treatment with compound II) resulted in 52% T / C, whereas 100 mg / kg and 200 mg / kg treatment resulted in more sustained pathway inhibition than the two higher dose levels. Consistently, these treatments resulted in 47% and 88% tumor regression, respectively.

[0232] To further evaluate the antitumor activity of the compound of formula (II), Formula (II) in 23 patient-derived xenograft (PDX) models from patients with A large-scale in vivo screen of the efficacy of compounds of formula (I) was performed ( FIG. 12 ). Tumor response was evaluated using I) Waterfall plot of the best mean tumor volume change rate for compound treatment The data were presented as a set of tumours, each of which was annotated with its mutation status in RAS or BRAF. Compound of formula (II) administered daily at 60 mg / kg or 200 mg / kg (▼) NSCLC PDX tumors (which harbor B-Raf, N-Ras or KRAS mutations) tumor growth inhibition in a subset of subjects (tumors enriched among better responders) One of the B-Raf mutant tumors, HLUX1323, showed that the IL-16 expression was mediated by Raf dimerization. The D594N mutation, which has been shown to activate signal transduction via the formula (II ) compound caused 26% tumor shrinkage in this model. These data in inhibiting Raf monomers or dimers and oncogenic MEK / ERK signaling As a result of its selective activity, This further supports the anti-cancer efficacy of the compound of formula (II) in

[0233] Example 6: Synergistic effect of compounds of formula (II) with MEK inhibitors The compounds of formula (II) used as single agents or in combination over a wide dose range Growth inhibition of HPAF-II cells (KRAS mutant) was measured after treatment with cyclosporine or trametinib. Isobolograms and synergy scores were generated to assess the combination activity. As shown in Figure 3, the compound of formula (II) in combination with trametinib exhibited the same efficacy as the Loew et al. e Synergy scores were obtained to show that the compounds have a synergistic effect on inhibiting HPAF-II cell growth. was doing.

[0234] Evaluate the effect of combination therapy on signaling inhibition versus either agent alone To investigate the mechanism of action of the AFII inhibitor, nude mice bearing HPAF-II xenograft tumors were treated with a single dose of 100 mg / kg. A dose of the compound of formula (II), 0.3 mg / kg of trametinib or a combination of DUSP6 mRNA levels, as a measure of pathway activity, were measured after treatment with either one of the two inhibitors. The IL-11 binding domains of the IL-11 receptor agonist, ... and IL-11 receptor agonist were determined in tumor samples collected at multiple time points. Compound treatment reduced DUSP6 expression by 83% compared to vehicle control at 4 hours (hr) post-dose. This inhibition did not result in increased levels of DUSP6 at 16 and 24 hr post-administration. Similarly, trametinib treatment did not improve DUSP In contrast, the compound of formula (II) and tramethionine resulted in partial and transient inhibition of 6. Combination with rifapril provided more sustained DUSP6 inhibition, with 8% inhibition even at 16 hours post-dose. The results showed >0% inhibition. Evaluating the antitumor efficacy of different treatments in the same tumor xenograft model Tumor-bearing animals were administered vehicle, 100 mg / kg qd of the compound of formula (II). , 0.3 mg / kg qd trametinib, or a combination of both, was administered for 10 days (Figure 15) Consistent with DUSP6 inhibition, the combination of the compound of formula (II) with trametinib Treatment with the compound of formula (II) results in greater antitumor activity than either of the single agents alone. or 33% compared with 40% T / C or 54% T / C with trametinib, respectively. In summary, these data indicate that the compound of formula (II) Combination treatment with trametinib inhibits the activity of MAPK pathway-associated gain-of-function mutations. Achieving greater and more durable responses in patients with an activated MAPK pathway It is suggested that the compound of formula (I) in combination with trametinib is Achieved greater and more durable responses than either alone, and was induced by a gain-of-function mutation in the MAPK pathway and improving antitumor activity in patients with activated MAPK pathways due to is also expected.

[0235] Incorporation by Reference All publications, patents and accession numbers referred to herein are each independently incorporated by reference. The patents are incorporated by reference in their entirety as if each was specifically and individually indicated to be incorporated by reference. The entirety of which is incorporated herein by reference.

[0236] Equivalent While specific embodiments of the subject invention have been discussed, the above specification is intended to be illustrative and not limiting. Many variations of the present invention will become apparent upon review of this specification and the claims below. The full scope of the present invention, along with its full scope of equivalents, will be apparent to those skilled in the art. The scope of the present invention should be determined by reference to the present specification together with the claims and variations thereon. It is.

Claims

1. Formula (I) [Formula 1] or a pharma- ceutically acceptable salt thereof; (b) a MEK inhibitor; 23. A pharmaceutical combination comprising:

2. The MEK inhibitors include trametinib, PD0325901, PD184352, and references. Metinib, cobimetinib, AS-701255, AS-701173, pimasertib, R DEA436, RO4987655, RG7167 and RG7420 or their pharma- ceutical approved derivatives The pharmaceutical combination according to claim 1, wherein the compound is selected from the group consisting of an acceptable salt or solvate thereof. height.

3. The MEK inhibitor is trametinib or a pharma- ceutically acceptable salt or solvate thereof.

3. The pharmaceutical combination according to claim 1 or 2.

4. The pharmaceutical composition of claim 3, wherein trametinib is in the form of a dimethylsulfoxide solvate. A combination.

5. The pharmaceutical composition according to any one of claims 1 to 4, which is for simultaneous, sequential or separate administration. Pharmaceutical combination.

6. A pharmaceutical combination according to any one of claims 1 to 5 which is a fixed combination. .

7. The pharmaceutical composition according to any one of claims 1 to 5, which is a non-fixed combination. Match.

8. A pharmaceutical combination according to any one of claims 1 to 7 and at least one pharma- and an acceptable carrier.

9. A pharmaceutical combination or a combination according to any one of claims 1 to 7 for use in the treatment of cancer. The pharmaceutical composition according to claim 8.

10. The cancer expresses a MAPK mutation, or the cancer expresses an NRAS mutation or a K-RA mutation.

10. The pharmaceutical combination for use according to claim 9 or the pharmaceutical combination for use according to claim 9, A pharmaceutical composition for use.

11. The cancers include melanoma, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer, and uterine cancer.

11. The pharmaceutical composition for use according to claim 9 or 10, which is cervical cancer or pancreatic ductal adenocarcinoma (PADC). Pharmaceutical compositions for combination or use.

12. The pharmaceutical composition for use according to claim 9 or 10, wherein the cancer is colorectal cancer (CRC). Pharmaceutical compositions for combination or use.

13. The pharmaceutical combination for use according to claim 9 or 10, wherein the cancer is melanoma. or a pharmaceutical composition for use therein.

14. For use according to claim 9 or 10, wherein the cancer is non-small cell lung cancer (NSCLC).

2. A pharmaceutical composition for the pharmaceutical combination or use of:

15. The cancer is MUTYH-associated polyposis (MAP) colorectal cancer (CRC). A pharmaceutical combination for use or a pharmaceutical composition for use according to claim 9 or 10.

16. 11. The pharmaceutical combination for use according to claim 9 or 10, wherein the cancer is cervical cancer. Or a pharmaceutical composition for use.

17. The pharmaceutical combination or method for use according to claim 9 or 10, wherein the cancer is ovarian cancer. A pharmaceutical composition for use.

18. The medicament for use according to claim 9 or 10, wherein the cancer is pancreatic ductal adenocarcinoma (PADC). and pharmaceutical compositions for such combination or use.

19. The cancer is selected from the group consisting of BRAF, NRAS, KRAS mutations, and combinations thereof. For use according to any one of claims 9 to 18, characterized by a mutation in 2. A pharmaceutical composition for the pharmaceutical combination or use of:

20. The cancer is KRAS-mutated NSCLC (non-small cell lung cancer), NRAS-mutated melanoma, KRAS-mutated KRAS mutant ovarian cancer and KRAS mutant pancreatic cancer (e.g., KRAS mutant pancreatic ductal adenocarcinoma (PDAC)) The pharmaceutical combination for use according to claim 9 or 10, selected from the group consisting of Pharmaceutical compositions for use.

21. A compound of formula (I) for use in the treatment of cancer [chemical 2] or a pharma- ceutically acceptable salt thereof, and trametinib or a pharma- ceutically acceptable salt thereof. or a solvate thereof.

22. 22. The pharmaceutical composition for use according to claim 21, wherein the cancer is N-RAS mutated melanoma. combination.

23. 22. The pharmaceutical combination for use according to claim 21, wherein the cancer is NSCLC.

24. The NSCLC is a KRAS mutated NSCLC, a BRAF mutated NSCLC or a KRAS mutated NSCLC. For the use according to claim 23, wherein the patient is a patient with both heterologous NSCLC and BRAF-mutated NSCLC. A pharmaceutical combination of.

25. The NSCLC is caused by a BRAF V600E mutation or a BRAF non-V600E mutation.

24. The pharmaceutical combination for use according to claim 23, characterized in that

26. The method according to any one of claims 21 to 25, wherein the cancer is an advanced or metastatic cancer. Pharmaceutical combinations for use.

27. The cancer is a BRAF V600 mutant melanoma or a BRAF V600 mutant NSCLC. and optionally the melanoma is treated with a BRAF inhibitor, such as dabrafenib or with vemurafenib and / or MEK inhibitors, such as trametinib or cobimetinib 22. The pharmaceutical combination for use according to claim 21, wherein the patient is no longer responding to treatment with

28. The cancer is responding to treatment with a combination of dabrafenib and trametinib or to treatment with Vemurafenib. BRAF V600 is resistant to treatment with a combination of phenytoin and cobimetinib 28. The pharmaceutical combination for use according to claim 27, which is a mutant melanoma.

29. The cancer is resistant to treatment with a combination of dabrafenib and trametinib. The pharmaceutical composition for use according to claim 27, wherein the patient is a BRAF V600 mutated NSCLC. Match.

30. The cancer, e.g., NSCLC or melanoma, is either in the setting of standard treatment or is not in the setting of an effective standard treatment. The use according to any one of claims 21 to 27, which is currently underway for those in whom no therapy exists. A pharmaceutical combination for use.

31. Used in combination therapy with trametinib or a pharma- ceutical acceptable salt or solvate thereof. For use in a compound of formula (I) [C3] or a pharma- ceutically acceptable salt thereof.

32. Formula (I) [C4] or a pharma- ceutical acceptable salt thereof. A nib or a pharma- ceutically acceptable salt or solvate thereof.

Citation Information

Patent Citations

  • Biarylamide compounds as kinase inhibitors

    JP2016517417A